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This dissertation focuses on the role of palmitoylation in regulating the sodium 
hydrogen exchanger isoform 1 (NHE1) and associated cellular functions as well as how 
various phosphorylation pathways alter NHE1 palmitoylation. Palmitoylation is the only 
known reversible lipid modification, allowing for the dynamic regulation of palmitoylated 
proteins not found with other lipid modifications. NHE1 regulates intracellular pH (pHi) by 
exchanging an extracellular sodium for an intracellular hydrogen.  Additionally, NHE1 is 
involved in regulating cell volume, cytoskeletal organization, protein anchoring, cell 
migration, and cell proliferation. NHE1 is highly regulated by protein interactions and 
modifications including phosphorylation. To begin, the first study shows NHE1 is 
palmitoylated in cells and rat tissues and can be inhibited by 2-bromopalmitate (2BP), a 
global inhibitor of palmitoylation. Furthermore, inhibition of palmitoylation with 2BP 
affects multiple NHE1 associated cell functions including pHi, stress fiber formation, 
proliferation and migration.  
 Continuing to look NHE1 regulation, we used various agonists known to effect 
NHE1 phosphorylation followed by examination of NHE1 palmitoylation. Serum, 
lysophosphatidic acid (LPA) and phorbol 12-myristate (PMA) treatments all increased 
NHE1 palmitoylation while insulin decreased NHE1 palmitoylation. Multiple studies have 
shown that palmitoylation and phosphorylation within the same protein can impact each 
other in various ways and thereby work together to regulate protein function. As NHE1 is 
highly phosphorylated, we also utilized specific kinase inhibitors and measured the effect 
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on NHE1 palmitoylation. We found inhibition of PI3K, AKT, Rsk, and ROCK increased NHE1 
palmitoylation while MEK inhibition decreased NHE1 palmitoylation. Together these 
studies establish a role for palmitoylation in the regulation of NHE1 activity and associated 
cellular functions and demonstrate palmitoylation and phosphorylation events may work 
in a coordinated manner to regulate NHE1. 
CHAPTER I 
BACKGROUND 
Post-Translational Modifications  
Proteins are the basis of cellular and physiological functions and their chemical 
and physical properties regulate activity and function within the cell1,2. Cellular proteins 
are regulated by a diverse range of chemical modifications on their amino acid side chains. 
These various modifying groups can affect charge, hydrophobicity, and other aspects of 
protein chemistry, resulting in marked changes in the behavior of protein molecules and 
hence in the control of physiological mechanisms3. Protein posttranslational 
modifications (PTMs) alter the physiological properties of proteins to change their 
behavior. PTMs are found in both eukaryotes and prokaryotes, being more common in 
eukaryotes where about 5% of the genome is dedicated to enzymes that carry out more 
than 200 types of PTMs45. PTMs are the attachment of specific chemical groups to amino 
acid side chains that occur both enzymatically or nonenzymatically2,5. Examples include 
phosphorylation, glycosylation, acetylation, methylation, sumoylation, palmitoylation, 
biotinylation, ubiquitination, nitration, chlorination, glycation, nitrosylation, acetylation, 
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and succination2,6. PTMs are important regulatory processes endowing proteins with the 
functional complexity that is essential for the maintenance of protein homeostasis within 
the cell.  
Depending on the biological purpose of a modification on a specific protein 
reversibility may or may not be beneficial. Reversible PTMs allow for control of intensity 
and duration of the effect without the need to degrade the protein to end the desired 
effect. Important functions of reversible posttranslational modifications include 
maintenance of protein homeostasis as well as the ability of proteins to rapidly respond 
to changing extracellular and intracellular signaling7.  Phosphorylation, acetylation, 
ubiquitylation, and S-palmitoylation are forms of covalent modifications that are readily 
reversed5. Reversible PTMs have dedicated enzymes, often large families of enzymes, that 
catalyze the addition and/or removal of covalent modifications5. This allows for protein 
regulation to occurring in both a spatial and temporal manner, which is vital for proper 
regulation of signaling.  Phosphorylation is the quintessential reversible modification 
providing a good example of the importance and complexity of this type of dynamic 
regulation.  
Phosphorylation is the reversible addition of a phosphoryl group from adenosine 
triphosphate (ATP) to primarily serine, threonine, or tyrosine residue and is broadly 
considered the most common posttranslational modification2,8.  Phosphorylation 
introduces a charged phosphate group which induces an altered conformational change 
that can affect catalytic activity of proteins, the tendency of proteins to aggregate, and 
the ability to recruit binding partners, all of which result in altered protein function and 
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cell signaling2,5. This conversion of a neutral OH side chain to dianionic phosphate 
provides a useful conformation switch in protein-domain restructuring, as such it has 
evolved into the major recurring theme in eukaryotic proteome diversity5.   
Protein kinases, which add the phosphate to a protein, remain in a basal “off” 
state in the absence of a specific stimuli, once a signal is propagated, the kinases become 
active and are able to modify their target proteins. Controlling the duration and intensity 
of signal transduction is vital for proper protein signaling, as such the signals need to be 
turned off and, in this case, phosphatases hydrolytically remove the PO32- group5. There 
are approximately 500 kinases and 150 phosphatases encoded by the human genome 
resulting in an almost infinite number of combinations creating amazing complexity9,10.  
Lipidation is a general term encompassing the attachment of different lipids and 
lipid-like groups onto proteins11. Protein lipidation is unique as it is structurally versatile 
and directly controls the attachment of soluble proteins to cell membranes without the 
requirement of other mediators4. Lipid modifications function to increase protein 
hydrophobicity can impact protein structure, localization, spatial distribution, membrane 
affinity, protein-protein interactions, and protein dynamics12. Covalent protein lipidation 
can occur enzymatically or nonenzymatically.  Among the many lipid classes enzymatic 
modifications include myristylation, farnesylation, geranylation, and palmitoylation 
shown in Table 1. Palmitoylation is unique as it is the only known reversible lipid 
modification4. As such palmitoylation is crucial for the regulation of cellular plasticity due 
to the effects on the physical properties of proteins which therefore alter protein activity, 
localization, and membrane association. 
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Additionally, lipid modifications can, and often do, work together to increase 
intensity and duration of soluble protein membrane association5,13. Classically a single 
lipid tether provides hydrophobicity for a strong but kinetically unstable association with 
the membrane. Once another lipid is added there is a noticeable decrease in membrane 
off-rates, from as fast as one minute with a single tether to as long as multiple hours once 
another lipid is added. This greatly stabilizes the association of the protein with the 
membrane and enables increase vesicular trafficking14,15.  
Palmitoylation  
S-acylation is a highly conserved process occurring in all eukaryotic organisms that 
have been examined and regulated by enzyme families that are conserved from yeast to 
humans. No evidence exists to show s-acylation occurs in prokaryotes, but many viral 
proteins can undergo s-acylation by hijacking host cell machinery3. S-acylation is the 
addition of a fatty acid, typically a saturated 16-carbon palmitate due to a combination of 
availability and affinity, to cysteine residues via a thioester bond. Enzymatic 
palmitoylation is catalyzed by palmitoyl acyltransferases (PATs) first identified in yeast. 
Genetic and biochemical studies showed these PAT enzymes share a highly conserved 
Asp-His-His-Cys domain termed the DHHC motif, resulting in these palmitoylating 
enzymes often being referred to as DHHCs16–18.  
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  Table 1. Types of Protein Lipid Modifications. This table demonstrates the various 
types of enzymatic lipid modifications, type of linkage, enzymes involved, and the lipid 
species. Important to note is the addition of a palmitate to a cysteine residue is the 
only known reversible lipid modification. Image copied with permission from 
Chamberlain and Shipston, 2015. 
Table 1. Types of Lipid Modifications 
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Palmitoylating Enzymes  
The family of genes that encode the DHHCs are found in all eukaryotes with 
numbers ranging from five in yeast to 23 in humans19. DHHC proteins are transmembrane 
proteins with four to six transmembrane domains. The conserved DHHC motif located on 
the cytoplasmic face between the second and third transmembrane domain and is 
essential for enzymatic activity as it provides the necessary cysteine for the two-step 
kinetic mechanism. To begin, the DHHC protein autoacylates using an acyl-CoA donor 
forming a transient acyl-enzyme intermediate. Then the fatty acid, typically palmitate, is 
transferred to the protein substrate20. The C- and N-terminal tails are highly varied and 
typically contain domains involved in protein-protein interactions including, ankyrin 
repeats, SH3 domains, and PDZ-binding motifs.  
This variation likely contributes to the substrate specificity seen with DHHC 
enzymes21,22. Some DHHC proteins appear to have a broad substrate specificity such as 
DHHC3 which has been show to palmitoylate both soluble and transmembrane proteins 
and is localized in the Golgi which is thought of as the hub of palmitoylation for soluble 
proteins. DHHCs also display specific subcellular localization (Table 2) with the majority of 
DHHCs residing in the ER and Golgi and a few found at the plasma membrane or in 
vesicles23–25. Additionally, some DHHCs such as DHHC2 cycle between the endosomes and 
plasma membrane26. This specific subcellular localization regulates access to substrates 
and contributes to selectivity. More recently is has been found that certain DHHCs are 
more common in specific tissues and others are expressed in only select tissues as can be 
seen in Table 327. While the discovery of DHHCs as palmitoylating enzymes occurred in 
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200216,17 many of the enzymes were already known to be involved in various physiologies 
and diseases, as such they were given different names which are still often used. Some of 
the most common examples include DHHC3, named GODZ, important for the 
palmitoylation of AMPA and NMDA receptors thus playing a role in regulating the 
excitation and inhibition balance in the brain which when abnormal could lead to various 
neurological disorders25,28,29. DHHC17 was first identified as HIP14 (huntingtin-interacting 
protein) and palmitoylates huntingtin, the major protein involved in Huntingtin Disease, 
as well as other select neuronal proteins such as SNAP-25 and PSD-95. DHHC17/HIP14 
plays an important role in regulating huntingtin and is implicated in the pathophysiology 
of Huntingtin Disease25,30,31. Other DHHCs that are related to specific disease include, 
DHHCs 6,9, and 21 implicated in Alzheimer’s Disease, DHHC8 in schizophrenia and bipolar 
disorder, and DHHCs 9 and 15 in X-linked intellectual disability25.  Consequently, 
understanding the regulation of palmitoylation via DHHCs is vital for understanding both 
healthy physiology and disease.  
Depalmitoylating Enzymes 
In contrast to the more detailed study of DHHCs, much less is understood 
regarding depalmitoylating enzymes.  Palmitoyl protein thioesterase 1 (PPT1) is a member 
of the α/β serine hydrolase family and was characterized as a thioesterase through 
observations that it depalmitoylates H-Ras32. PPT1 localizes exclusively to lysosomes and 
late endosomes which separates PPT1 from substrate targets in the cytosol or at the 
plasma membrane33.  
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  Figure 1. DHHC Mechanism. For S-palmitoylation palmitic acid is transformed to 
palmitoyl-CoA. The palmitoylating enzymes then use a ping-pong mechanism where 
the palmitate group is transferred from the CoA to the open thiol in the DHHC region 
of the palmitoylating enzyme creating a transient acyl-intermediate. The palmitate is 
then transferred to the free thiol on the substrate resulting in a palmitoylated protein. 
Image copied with permission from De and Sadhukhan, 2018.  
 
 
Figure 1 DHHC Mechanism 
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  Figure 2. Schematic of DHHC Enzymes. This figure shows representative isforms of  
DHHCs showing their diversity and similarities. DHHCs all have the conserved DHHC 
active site but can vary in the number of transmembrane domains, regulatory domain, 
and binding sites. Image copied with permission from Tabaczar et al., 2017 
 
 




Table 2. DHHC Subcellular Localization. This table shows the known cellular localization 
of the different DHHC isoforms. While most DHHC reside in the ER and Golgi some are 
plasma membrane specific, with specific localizations such as neuronal spines and 
presynaptic terminals. This localization compartmentalizes the DHHCs which likely 
plays a role in regulating access to specific substrates. Image copied with permission 
from Cho and Park, 2016.  
 
Table 2. DHHC Subcellular Localization 
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Table 3. DHHC Tissue Distribution 
Table 3. DHHC Tissue Distribution. This table highlights that specific DHHC enzymes are 
found in specific tissues. The same DHHC isoform may be found in multiple tissues 
however not every DHHC is found in every tissue. This distribution may play an 
important role in substrate access or change the available DHHC binding partners 
regulating DHHC activity. Image copied with permission from Korycka et al., 2012.  
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PPT1 dysfunction has been implicated in infantile neuronal ceroid lipofuscinosis, 
a neurodegenerative disorder where lipid thioesters from acylated proteins accumulate 
in the lysosome causing devastating decreases in motor skills and speech with the 
development of seizures and death between age 9-1134.  Palmitoyl protein thioesterase 
2 (PPT2) is lysosomal specific and shares roughly 18% homology with PPT1. PPT2 is not 
able to depalmitoylate the same proteins as PPT1 demonstrating that PPTs also display 
substrate specify like PATs. Mutation of PPT2 also appears to cause a milder form of 
infantile neuronal ceroid lipofuscinosis35.  Due to the localization of PPT1 and PPT2, 
neither are likely to contribute to depalmitoylation at the plasma membrane, instead 
contributing to lysosomal degradation of palmitoylated proteins and potentially playing a 
role in vesicular depalmitoylation.  
Acyl protein thioesterases (APTs) are also members of the α/β serine hydrolase 
family and were originally purified from rat liver as lysophospholipases (lypla). APTs can 
hydrolyze multiple lysophospholipids and long-chain mono-acyl glycerol esters, at a much 
lower catalytic efficiency than palmitoylated substrates36. Three isoforms have been 
identified APT1, APT2 and APTL1 all of which are cytosolic proteins with the ability to 
interact with internal membranes and the plasma membrane.  APT1 and APT2 share 81% 
homology and were originally thought to be redundant. Study of these enzymes have 
been limited due to the lack of antibodies, leading to most studies being done with GFP 
or HA tagged proteins. Overexpression of APT1 leads to decreased palmitoylation of small 
GTPase, endothelial nitric oxide synthase, and other soluble proteins in cells37. Recent 
studies have shown APT1 and APT2 are not redundant and do display substrate 
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specificity38,39. One interesting detail is that both APT1 and APT2 are palmitoylated, with 
APT1 being able to depalmitoylate both isoforms and APT2 been shown to only 
depalmitoylate itself but not APT1, adding complexity to the regulation of 
palmitoylation.37,40. Use of inhibitors has aided in the study of endogenous APTs, 
specifically the recent development of isoform specific inhibitors ML348 (APT1) and 
ML349 (APT2)41. APTL1 is a homologue of APT1 with 31% similarity, however structurally 
APTL1 is more similar to PPT2 with a narrow substrate binding pocket which prefers short-
chain substrates. Currently, no protein substrates have been identified for APTL125.  
While the study of APTs is ongoing and improving with the development of specific 
antibodies, many researchers found that APTs and PPTs alone could not explain all 
depalmitoylation. This reinvigorated the search for new depalmitoylating enzymes, 
specifically within the α/β serine hydrolase family and resulted in the discovery that ABHD 
enzymes can depalmitoylate proteins as well. Lin and Conibear found that ABHD17 
depalmitoylates N-Ras, but not APT1 or APT242. Three isoforms, ABHD17A, 17B, and 17C 
are also able to depalmitoylate PDS-9543. This indicates there may be more 
depalmitoylating enzymes  
Cellular and Physiological Roles of Palmitoylation  
Palmitoylation is the only known reversible lipid modification, as such 
palmitoylation plays an important role in the dynamic regulation of cellular proteins. 
Palmitoylation of a protein can tether it to membranes as well as direct proteins to 
specific membranes or membrane domains rich in cholesterol referred to as lipid rafts. 
Soluble proteins such as the Ras family provide a classic example of proteins whose 
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localization is dynamically regulated by palmitoylation. H-Ras and N-Ras are palmitoylated 
in the Golgi which then stabilizes their association with the membrane to facilitate 
vesicular trafficking to the plasma membrane where they function as important signaling 
molecules. Depalmitoylation at the plasma membrane then releases H/N-Ras to the 
cytoplasm, ending the signaling in which they are involved and allows its return to the 
Golgi, where the cycle can begin again15,44,45. Similar palmitoylation driven protein cycling 
has been documented for multiple other signaling molecules include G-proteins, kinases, 
synaptic proteins, and even depalmitoylating enzymes14,46–49. The rapid and dynamic 
nature of palmitoylation is akin to phosphorylation. However, it should be noted that 
rapid cycling of acyl chains on palmitoylated is not universal and low turnover rates can 
occur3 adding to the complexity.  
Palmitoylation of soluble membrane proteins promotes stable membrane 
binding, which as mentioned above is important even for dual lipidated proteins as a 
single myristoyl or prenyl group is not sufficient to provide a strong membrane 
interaction. As the enzymes that mediate palmitoylation are exclusively transmembrane 
proteins (see above) the weak association provided by a single irreversible lipid group is 
likely important for mediating the interaction between soluble proteins and the 
membrane to facilitate palmitoylation. Again, the Ras protein family provides an example 
of this. When the palmitoylation sites are mutated Ras proteins still show a weak 
association with the membrane, however when the farnesylation site is mutated loss of 
both palmitoylation and membrane association is seen50. Combining palmitoylation, a 
reversible lipid modification, with another irreversible lipid modification such as 
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prenylation or myristylation is a powerful way to regulate soluble protein membrane 
association as well as providing dynamic regulation of signaling proteins5,15,45,51.  Of note 
some soluble proteins are exclusively palmitoylated with no obvious primary membrane 
targeting signals, such as SNAP25 an important component of the SNARE complex; it is 
suggested that such proteins rely on weak intrinsic membrane affinity to undergo 
palmitoylation52. Additionally two important neuronal proteins PSD-95, which functions 
to scaffold glutamate receptors at the post-synaptic membrane, and GAP43, which is an 
important component of the axonal growth cone rely solely on palmitoylation at multiple 
cysteines for their membrane tethering with the combination of palmitoylation sites 
being important for regulation of these factors14,15. 
Lipids within cell membranes are diverse and can form microdomains rich with 
cholesterol and saturated phospholipids, typically termed lipid rafts. Multiple studies 
have been done to understand the physiologic importance of these lipid enriched areas, 
with recent studies revealing palmitoylated proteins largely copurify with cholesterol-
enriched detergent-insoluble membranes.53 Further study showed palmitoylation plays 
an important role as a regulator of lateral distribution of proteins within the membrane 
and that palmitoylation is an important signal for sequestrating proteins to lipid rafts54.  
This palmitoylation dependent association of proteins to lipid rafts regulates important 
cellular pathways such as actin cytoskeleton remodeling via Rac155 and SNARE mediated 
exocytosis via SNAP2556,57 demonstrating an important physiologic role for lipid rafts and 
palmitoylation.  
Palmitoylation is also known to increase protein stability by preventing 
 17 
ubiquitination thus decreasing protein degradation4,21. The interplay between 
palmitoylation and ubiquitination was reported for Tlg1, a SNARE protein, where 
palmitoylation alters the position of the transmembrane domain preventing acidic 
residues from associating with the membrane which is a signal for Tul1-mediated 
ubiquitination58. Additionally, proteomic analysis has been performed on mice with 
reduced expression of palmitoylating enzymes noting that decreased palmitoylation of 
proteins often correlated with an overall loss of expression3.  
Palmitoylation effects the localization of soluble membrane proteins by 
promoting accumulation of palmitoylated proteins on membranes containing the specific 
palmitoylation and depalmitoylation enzymes that act on that protein. Palmitoylation can 
also promote clustering of proteins within various membrane compartment as is the case 
with Ras trafficking. This allows for Ras signaling to be compartmentalized, with different 
Ras isoforms distributed within the Golgi stack based on di- and mono- palmitoylation 
events which aid in the theory that Ras proteins signal from the Golgi4,59.  
Since transmembrane proteins do not require palmitoylation for membrane 
localization the role of palmitoylation in trafficking is more prevalent and potentially 
easier to study than in soluble proteins. Trafficking from the ER after translation is 
dependent on proper topological arrangement of the protein. Various chaperons and 
enzymes in the ER lumen facilitate protein folding and catalyze modifications such as 
glycosylation which are important for the assembly of proteins by facilitating folding, 
subunit assembly and dimerization necessary for proper trafficking60. A large number of 
palmitoylating enzymes are found in the ER indicating palmitoylation plays an important 
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role in proper protein assembly61. LRP6 is a single transmembrane protein that is 
palmitoylated near the cytoplasmic side of the transmembrane region. When LRP6 
palmitoylation sites are mutated the protein is retained in the ER, likely due to 
hydrophobic mismatching that occurs between the transmembrane domain and the ER 
bilayer. Palmitoylation reduces this mismatch by titling the transmembrane domain and 
promoting trafficking of LRP6 to the plasma membrane62. Trafficking of membrane 
proteins between the plasma membrane and endosomal system is also a common role of 
palmitoylation, where the ability of a protein to be internalized can be altered by the 
palmitoylation status as seen with AMPA and NMDA receptors. This is important to 
consider as many proteins only function at the plasma membrane, thus studying 
expression levels alone may not be sufficient to draw certain conclusions. In addition to 
altering surface expression, palmitoylation can also affect endosomal accumulation of 
proteins, such as MUC1, and impact protein cycling between endosomes and the Golgi as 
seen with Sortillin3. Palmitoylation plays a clear role in protein trafficking of both soluble 
and transmembrane proteins, leading to an important role for palmitoylation in 
regulating protein expression, signaling, and function.  
 Palmitoylation plays an important role in protein localization and thus can 
facilitate or inhibit protein-protein interactions. Palmitoylation can affect this interaction 
through steric hindrance, conformational changes, and/or interaction of cytoplasmic 
protein segments to the membrane interface. The generation of protein platforms 
through palmitoylation creates dynamic multiprotein complexes which can contain both 
palmitoylated and non-palmitoylated proteins. Oligomerization of proteins can also be 
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promoted by palmitoylation, which can alter protein functionality63,64. Direct proof that 
palmitoylation is required for the function of a given transmembrane protein can be 
difficult to prove as function is often dependent on localization and protein interactions. 
However, this does demonstrate the importance of palmitoylation in regulating both 
duration and intensity of protein activity.  
 Typically, when a palmitoylation site is found in close proximity to a 
transmembrane region the conformation of the domain and thus the function of the 
protein can be altered. Palmitoylation can increase the hydrophobic length of the domain 
and/or the orientation of the domain with respect to the bilayer. Tilting of the 
transmembrane domains are important, especially when considering the thickness of the 
membrane, as mentioned above with LRP6. Membrane thickness typically increases from 
the ER to the Golgi to the plasma membrane; additionally, the curvature of the membrane 
and cholesterol content can affect membrane thickness. If the transmembrane domain is 
too long or too short, it can lead to a hydrophobic mismatch which can have detrimental 
effects on the protein.  Palmitoylation is typically used to reduce this mismatch by titling 
the membrane and allows for proper processing especially from the ER to the Golgi.  
Palmitoylation, like phosphorylation, has been implicated in a diverse range of 
physiological processes. These processes include but are not limited to synaptic plasticity, 
host-pathogen interactions, innate immunity, cell death, metabolism, cell polarity and 
migration, and membrane trafficking. As palmitoylation affects so many vital cellular 
processes it can be implicated in almost any disease either directly or indirectly, making 
understanding the regulation of proteins by palmitoylation important for numerous 
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pathologies.  
Sodium Hydrogen Exchanger Isoform 1 (NHE1)  
Similar to how palmitoylation can be implicated in a broad range of diseases 
ubiquitously expressed proteins, especially those that regulate basic cellular functions, 
are also implicated either directly or indirectly in a broad range of diseases. Intracellular 
pH (pHi) is one of these basic systems that is regulated by the sodium hydrogen exchanger 
isoform 1 (NHE1). NHE1 is a ubiquitously expressed transmembrane protein that 
exchanges an intracellular hydrogen for an extracellular sodium to regulate pHi and 
control cell volume65. The study of NHE1 was greatly enhanced when Pouyssegur et al 
used a highly specific proton suicide technique on Chinese hamster lung fibroblast 
(CCL39), which express only isoform 1 of NHE, to create mutant cells lacking NHE1 
expression (PS120)66. Later human NHE1 was transfected into these cells resulting in the 
PSN cell line which now expresses human NHE1 as the main regulator of pHi, making these 
cell lines the gold standard to study NHE1 activity via pHi measurement.  
NHE1 Physiology  
 Regulation of pH and control of cell volume are the most basic roles of NHE1 these 
factors also have wide ranging implications on many cell processes such as cell migration, 
cell proliferation, vesicle trafficking, apoptosis, cell survial67 and cell metabolism68,69. In 
fibroblast type cells NHE1 preferentially localizes to the leading edge of lamellipodia, 
where ion transport creates an alkaline intracellular environment paired with an acidic 
extracellular environment. This allows for actin stress fibers to form at the membrane70 
while simultaneously aiding in the degradation of the extracellular matrix allowing for 
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increased cell migration and invasion. Multiple studies have shown that the presence of 
NHE1 is essential for proper directional cell migration71,72. Recently, NHE1 has been 
shown to play a role in lysosome trafficking to the cell periphery in the prostate73. 
Additionally, NHE1 acts as a protein scaffold, binding many partners including PIP2, ERM, 
calmodulin and CHP1/2 and various posttranslational modifications74,75. Through this 
scaffolding, NHE1 contributes to various cell signaling processes in ion independent and 
dependent manners with the binding of proteins and addition of modifications having 
been shown to alter transport activity76–78.  
 NHE1 has also been well researched in specific organ systems, especially the 
cardiovascular system where NHE1 is a central regulator of cardiomyocyte pHi and 
contractility79 and is localized to the plasmalemma, intercalated discs, and transverse 
tubules. Cardiac pHi changes during increased cardiac workload and heart rate with 
increased NHE1 activity contributing to cardiac ischemia-reperfusion damage and 
hypertrophy80.  NHE1 is also found in the vasculature in both smooth muscle and 
endothelial cells. Based on several studies in mice and cells, NHE1 is thought to play a role 
in pulmonary artery remodeling, angiogenesis, volume control and fibronectin 
production76,81. NHE1 is also essential for the central nervous system, where studies using 
NHE1 knockout mice show abnormal neuronal excitability, epilepsy from Na+ 
permeability, and death before weaning. Other studies show NHE1 playing a role in 
several neurological diseases including dementia, specifically Alzheimer’s Disease, 
neuropathic pain, and cerebral ischemia82. In the central nervous system (CNS) NHE1 
regulates pHi in neurons, glial cells, and microvascular endothelial cells. The mechanisms 
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surrounding the role of NHE1 in the CNS are largely unknown. Most studies have focused 
on the role NHE1 plays in glioblastoma multiform, an aggressive cancer of the glial cells, 
as the role of NHE1 in cancer has been clearly established83–85. A number of mitogenic 
factors have been shown to activate NHE1 resulting in increased cell growth, 
proliferation, migration, and invasion, all processes important for the neoplastic 
transformation and maintenance of malignant cells. The pHi of malignant cells is more 
basic than that of the corresponding nontransformed cells, thus disturbance of pH 
homeostasis has been thought to correspond to an increased cancerous state86. NHE1 has 
been implicated in a number of cancers apart from glioblastoma, including but not limited 
to breast87,88, prostate89, ovarian, and lung90,91. Recent interest has surrounded the role 
NHE1 plays in activation of brain microglial cells and how this may contribute to brain 
focal ischemia92. In addition, activation of brain microglia and increased inflammation has 
been shown to play a role in neurodegenerative disease, specifically Alzheimer’s Disease, 
indicating NHE1 could play a bigger role in neurological diseases than originally thought. 
Furthermore NHE1-mediated pH-regulation has been shown to be important for IgE-
induced macrophages and correctly functioning neutrophils76,93,94.  
NHE1 Structure  
Human NHE1 (hNHE1) is an 815 amino acid protein with the first 500 residues 
making up 12 transmembrane spanning segments with interconnecting loops and the last 
315 comprising an intracellular tail. Due to the difficulties associated with crystallizing 
membrane proteins, relatively little is known about the structure of NHE1.  Some insight 
has been provided by the crystallization of the E. Coli Na+/H+ antiporter (NhaA) by Hunte 
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et al (2005) which shows structural similarity to hNHE195,96. Additional various molecular 
biology techniques have been employed to gain a general understanding of NHE1 
structure. Substituted-cysteine-accessibility analysis was used to confirm the 12 TM 
domain topology and that the N- and C-termini were cytosolic. It also identified three 
membrane associated regions, intracellular loop 2 (IL2), intracellular loop 4 (IL4) and 
extracellular loop 5 (EL5), which may be important in for NHE1 function. The transport 
function of NHE1 occurs in the N-terminal half of the protein (first 500 residues) with TM 
IV, TM VII, TM IX, and TM XI containing residues that are important for ion binding and 
transport97. The C-terminal region (315 amino acids) is completely intracellular and 
considered the regulatory domain of NHE1. The membrane proximal region (503-685) 
termed the predicted folded domain is 50% random coil with 35% of that being a-helix 
and the membrane distal domain (686-815) being intrinsically disordered98,99. The 
proximal region contains multiple protein binding sites while the distal region has multiple 
phosphorylation sites which operate to regulate NHE1 function and are described in 
greater detail below.  
NHE1 Binding Partners 
 Phosphatidylinositol 4,5-bisphosphate (PIP2) is a signaling phospholipid at the 
plasma membrane that can be converted into other signaling molecules that are 
important 2nd messengers. NHE1 has two PIP2 binding sites (513-520 and 556-564) and 
studies show loss of PIP2 binding inhibits NHE1 function making the NHE1-PIP2 interaction 
important for proper regulation69,100,101. Calcineurin homologous protein 1 (CHP1) also 
binds NHE1 in the proximal membrane region between residues 510-530. The association 
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between CHP1 and NHE1 is essential as interrupting this interaction results in a dramatic 
loss of NHE1 activity102. Overexpression of CHP1 in fibroblast cells leads to inhibition of 
serum stimulated proton transport, while mutations of the CHP1 binding site on NHE1 
reduce proton sensitivity and decrease NHE1 activity103,104. It is thought that the CHP1-
NHE1 interaction promotes an NHE1 structure with a more available proton sensing 
domain, preserving pHi sensitivity of NHE1101. Additionally, CHP2, which is highly 
expressed in tumor cells, interacts with NHE1 and protects cells from serum deprivation 
induced cell death by increasing pHi to maintain the malignant state of transformed 
cells103.  
Ezrin, radixin, and moesin (ERM) proteins form a complex at the plasma 
membrane that provides an important link between the plasma membrane and actin 
filaments that form the cytoskeleton. NHE1 contains two ERM binding domains on the C-
terminal tail between residues 553-564 which directly mediates this interaction105. The 
cellular cytoskeleton is essential for maintaining cell shape and establishing mechanical 
and chemical properties within the plasma membrane. The ERM -NHE1 interaction directs 
NHE1 localization in the lamellipodia of migrating cells and if this interaction is disrupted, 
cells develop an irregular shape and have limited motility71. Additionally, the physical 
interaction of ERM proteins and NHE1 activates Akt, a pro-survival kinase which leads to 
stalled apoptosis75,106. Calmodulin (CaM) is a calcium binding protein that binds NHE1 to 
regulate pHi in response to calcium signaling. Binding of calcium and calmodulin to the 
high affinity site on NHE1 (636-656) activates NHE1 by blocking the autoinhibitory 
interaction thus regulating intercellular pH107.  NHE1 also has three consensus sites for N-
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linked glycosylation, N75, N370, and N410. Interestingly mutation of all three sites, 
individually and in combination, produced functional transporters with similar transport 
rate and pharmacological profiles to the wild type exchanger, however cleavage using 
endoglycosidase does result in reduced apparent size of NHE1 from 110kDa to 
90kDa108,109.  
NHE1 Phosphorylation 
NHE1 regulation by phosphorylation has been widely studied. Bioinformatic and 
mass spectrometry analysis has predicted multiple phosphorylation sites on the C-
terminal tail focused mostly on the distal end. Many of these phosphorylation sites have 
been experimentally validated along with the kinases involved and various stimuli 
including hormones, growth factors, and sustained intracellular acidosis97. Growth factor 
stimulation of fibroblast cells induces the MAPK (mitogen-activated protein kinase) 
cascade resulting activation of ERK1/2 (extracellular-signal-regulated kinase) leading to 
NHE1 activation. Inhibition of the ERK signaling cascade reduces growth factor stimulated 
NHE1 activation by 50-60%, a similar reduction is seen when ERK sites on NHE1 
(S770/771) are removed110. ERK2 also stimulates phosphorylation on S693, S766, S770, 
and S785, however, the importance of these residues needs to be further explored. ERK 
is also an upstream regulator of Rsk (p90 ribosomal S6 kinase), which phosphorylates 
NHE1 at S703111. Both the ERK and Rsk sites are important for invasion and migration of 
breast cancer cells. Additionally, the Rsk site (S703) can act independently of the ERK sites 
to control movement of tumor cells into and out of the circulatory system which is 
important for cancer metastasis112,113. Interestingly, stimulation of fibroblast cells with 
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platelet derived growth factor (PDGF), which activates the ERK/Rsk pathway, results in 
NHE1 mediated cell migration and cytoskeletal formation but not alteration of NHE1 
transport activity114. AKT phosphorylation is also required for NHE1 activation through 
PDGF stimulation. AKT phosphorylates NHE1 at S648 and activates NHE1 in fibroblasts, 
however, AKT phosphorylation of NHE1 in cardiomyocytes has an inhibitory effect70.  
ROCK (Rho-associated kinase p160ROCK) is a downstream target of RhoA (GTPase) 
which stimulates NHE1 via direct phosphorylation at T653. Both the ROCK and ERK 
pathways are required for full activation of NHE1 through growth factor receptor 
stimulation98. Apoptotic signals stimulate MAPK p38 which induces intracellular 
alkalization activating NHE1 through phosphorylation at  potential sites including T718, 
S723, S726, and S729115,116. Platelet derived growth factor activates NHE1 via NIK (Nck-
interacting kinase) phosphorylation at S638114,117. NHE1 activation through phorbol ester 
stimulation has also been shown, however, no direct PKC phosphorylation sites on NHE1 
have been found118,119. In addition, acidification stimulates CaMK II (Ca2+/calmodulin-
dependent kinase II) medicated NHE1 phosphorylation and contributes to increased 
NHE1 activity. Several other kinases including PKA, Raf, Pyk2 and Daxx have been found 
to bind and phosphorylate NHE1 but specific residues have not been found120. Figure 3 
displays these phosphorylation and binding partner sites on NHE1. Overall NHE1 is a 
highly modified protein, which is important for regulating activity as well as localization, 
protein scaffolding, and protein-protein interactions. Proper regulation of NHE1 is vital 
for maintaining cellular homeostasis. The presence of multiple cysteine residues on the 
C-terminal tail of NHE1 combined with its highly modified nature lead us to explore NHE1 
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palmitoylation and the role the regulation plays physiologically.  
 
Dissertation Research Objective 
 The objective of this dissertation is to demonstrate NHE1 is palmitoylated and 
inhibition of palmitoylation alters NHE1 associated physiology. As well as show 
preliminary evidence that multiple phosphorylation pathways that act to alter NHE1 
palmitoylation indicating palmitoylation and phosphorylation work in a coordinated 







Figure 3. Schematic Model of NHE1. This NHE1 diagram highlights the C-terminal tail 
showing the large number of phosphorylation sites and kinases involved. Also shown 
are various biding partners and their subsequent binding sites. Copied with 
permission from Wallert et al., 2016.   
 
Figure 3 Schematic Model of NHE1 
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Chapter II 
FUNCTIONAL CONSEQUENCES OF INHIBITING SODIUM HYDROGEN 
EXCHANGER 1 (NHE1) PALMITOYLATION 
Abstract 
Palmitoylation is a reversible lipid modification that regulates an array of protein 
functions including activity, trafficking, membrane microlocalization and protein-protein 
interactions. Identification of over 5000 proteins with this modification suggests that 
palmitoylation plays a critical role in regulation of many cellular processes. In this study 
we demonstrate for the first time a member of the SLC9 family, the sodium hydrogen 
exchanger isoform 1 (NHE1), is palmitoylated in both cells and rat tissue. In addition, 
using the irreversible PAT inhibitor 2-bromopalmitate (2BP) we have identified several 
cellular functions commonly associated with NHE1 are affected by decreased NHE1 
palmitoylation. Treatment of Chinese hamster lung fibroblast cells expressing human 
NHE1 with 2BP results in decreased palmitoylation. This treatment also resulted in 
decreased NHE1 activity, detected by measuring the change in intracellular pH. 
Additionally, PSN cell migration and proliferation was inhibited by 2BP in a manner 
consistent with the degree of inhibition of NHE1 palmitoylation. These results suggest 
that palmitoylation plays a major role in NHE1 regulation that could significantly impact 
multiple critical cellular functions.  
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Introduction  
The SLC9 transporter family is made up of transmembrane sodium hydrogen 
exchangers which function to regulate intracellular pH (pHi) by exchanging an intracellular 
proton for an extracellular sodium ion in various tissues75. Sodium hydrogen exchanger 
isoform 1 (NHE1) functions at the plasma membrane and is ubiquitously expressed 
throughout tissues121,122. Multiple cellular processes are associated with NHE1 activity 
including coordinated cell migration, cellular proliferation, and control of cell volume. 
NHE1 also functions as a membrane anchoring and scaffolding protein resulting in the 
formation of different protein complexes that participate in regulating signaling pathways 
within the cell123,124.  Regulation of NHE1 activity and function occurs within the 
regulatory domain found on the large intracellular C-terminal tail. Many binding partners 
and modifications occur within this regulatory domain and influence exchanger activity 
and trafficking. Major binding partners include PIP2100 and ERM71 which are important for 
association of the tail to the inner membrane leaflet and the formation of stress fibers, 
respectively123. Ca2+/calmodulin binding sites also on the C-terminal tail have been shown 
to play an important role in proton affinity and thus regulate NHE1 activity107. 
Additionally, multiple phosphorylation sites are also present on the C-terminus which 
have varying effects on NHE1 activity and the multiple cellular processes in which NHE1 
plays a role. Together these many regulatory factors control NHE1 activity, localization, 
and expression, all of which are important for regulation of critical cellular processes.  
S-Palmitoylation is the addition of a 16-carbon fatty acid to a cysteine residue via a 
thioester bond. Palmitoylation is a unique lipid modification because it is reversible, with 
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palmitoyl acyltransferases (PATs) adding the palmitate while acyl protein thioesterases 
(APTs) and palmitoyl-protein thioesterases (PPTs) remove the palmitate. The most well 
studied function of palmitoylation is trafficking of proteins between the organelles and 
increasing membrane association of cytosolic proteins. Recent studies have 
demonstrated that palmitoylation has multiple other effects on proteins, particularly 
transmembrane proteins where effects include regulation of protein activity, membrane 
microlocalization and protein-protein interactions125,126. Dysregulation of protein 
palmitoylation has been implicated in neurological dysfunction including Huntington and 
Alzheimer’s disease, multiple forms of cancer and many other diseases26,127–130.  
Due to the highly modified nature of the NHE1 C-terminal tail and the presence of 
multiple cysteine residues which are potential sites of palmitoylation we hypothesized 
that palmitoylation could be present on NHE1 playing a role in regulating activity and 
associated cellular functions. Using acyl biotinyl exchange (ABE) and metabolic 
incorporation of [3H]palmitate we showed NHE1 is palmitoylated in both cells and various 
rat tissues. Additionally, we used 2-bromopalmitate (2BP), an irreversible inhibitor of 
palmitoylating enzymes (PATs)131, to decrease palmitoylation of NHE1 in a time 
dependent manner. Using 2BP to decrease palmitoylation we also showed a decrease in 
pHi indicating palmitoylation plays a role in regulation of NHE1 activity. Additionally, 
stress fiber formation, cell migration, and cell proliferation were decreased upon 2BP 
treatment, all critical cellular functions regulated by NHE1. Together these data establish 
a role for the reversible lipid modification, palmitoylation, in the regulation of NHE1 
activity and associated cellular functions.  
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Materials 
Colorburst molecular mass standard, 2- bromopalmitate (2BP), and mouse anti-
flag tag antibody were from Sigma Millapore and anti-NHE1(54) mouse monoclonal 
antibody (sc-136239) was from Santa Cruz Biotechnology. MMTS (N-(6-
(biotinamido)hexyl)-3-(2-pyridyldi-thio)-propionamide), high capacity NeutrAvidin ®-
agarose resin, and bicinchoninic acid protein assay reagent was from Thermo Scientific. 
HPDP-biotin was from APExBio, BCECF-AM 2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-
carboxyfluorescein was from Molecular Probes and Nigericin was from Tocris Bioscience. 
LPA in the form of 14:0 1-myristoyl-2-hydroxy-sn-glycero-3phosphate (sodium salt) was 
from Avanti Polar Lipids and XTT(2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxyanalide) reagent from Trevigen.  
Methods 
Cell Culture 
 NHE1-null cells (PS120 cells, a gift from D. Barber, University of California, San 
Francisco) derived from Chinese hamster lung fibroblasts CCL339 were used to generate 
a stably expressing human NHE1 with HA DDK epitope tag on the C terminus labeled PSN 
cells.  These cells were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 20% fetal bovine serum, 2 mM L-glutamine, and 200 µg/ml G418 at 
37oC in a humidified 5% CO2 incubator after clonal isolation 98.  
Cell Treatments and Membrane Preparation for Palmitoylation Detection 
PSN cells were subcultured, seeded on 150 mm culture dishes, and grown to 
confluency and treated with experimental treatment conditions as described. After 
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treatment, cells were washed twice with 3 mL of ice-cold buffer B (0.25 M sucrose, 10 
mM triethanolamine, 10 mM acetic acid, pH 7.8) and then scraped to one side of the plate 
using 0.5 mL of buffer B and transferred to a 2 mL microcentrifuge tube on ice.  Cells were 
then pelleted by centrifugation at 3,000 x g for 5 min at 4oC. The supernatant fraction was 
removed and 1 mL of ice-cold buffer C (0.25 M sucrose, 10 mM triethanolamine, 10 mM 
acetic acid, 1 mM EDTA, pH 7.8) containing protease inhibitor was added to break the 
pellet loose. The solution containing the loose pellet was then homogenized in a Dounce 
homogenizer with 30 up and down strokes on ice.  The resulting homogenate was 
centrifuged at 800 x g for 10 min at 4°C to pellet and remove nuclei and cell debris. The 
supernatant fraction was transferred to a new tube which was centrifuged at 16,000 x g 
for 12 min at 4°C to precipitate cell membranes. The supernatant fraction was removed 
and the pellet containing cell membranes was resuspended in 1 mL sucrose-phosphate 
(SP) buffer (10 mM sodium phosphate, 0.32M sucrose, pH 7.4) and assayed for protein 
content. 
Metabolic Labeling of NHE1 with [3H]Palmitate 
PSN cells were metabolically labeled with [9,10-3H]Palmitic acid (0.5 mCi/ml) for 
indicated times at 37 °C in a-MEM, containing 1 mM sodium pyruvate to inhibit palmitate 
metabolism through fatty acid -oxidation132,133. After labeling, cells were washed with SP 
buffer and lysed in radioimmunoprecipitation assay buffer (RIPA; 10 mM sodium 
phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM sodium fluoride, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, pH 7.2). Lysates were then immunoblotted with anti-
DDK to determine NHE1 levels and volumes containing equal amounts of NHE1 (verified 
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by a second immunoblot) were immunoprecipitated with anti-DDK protein A beads. 
Precipitated NHE1s were resolved on 4-20% SDS-polyacrylamide gels, treated with 
Fluoro-Hance (Research Products International) fluorographic reagent for 30 min, dried, 
and exposed to x-ray film for ~ 60 days.  
Palmitoylation Detection using Acyl-Biotinyl Exchange (ABE) 
Adapted from Wan et al134 palmitoylated proteins are detected using three steps. 
(i) Free cysteine thiols are blocked; membranes isolated from PSN cells were solubilized 
in lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease 
inhibitors and 20 mM methyl methanethiosulfonate (MMTS) and incubated for 20 
minutes at 37oC, followed by acetone precipitation. Precipitated proteins were again 
solubilized in lysis buffer containing protease inhibitors and MMTS and incubated at room 
temperature with end over end mixing overnight. MMTS was removed by three 
consecutive acetone precipitations in which the protein pellet was resuspended in 4SB 
buffer (4% SDS, 50 mM Tris, 5 mM EDTA, pH 7.4) followed by acetone precipitation. (ii) 
Thioester linked palmitoyl groups are specifically removed by hydroxylamine (HAM); The 
resuspended protein sample is split equally into negative control (50 mM Tris-treated) 
and HAM-treated (0.7 mM) halves and incubated at room temperature for 15 min with 
end-over-end mixing. (iii) The previously palmitoylated and now free sulfhydryl groups 
are then biotinylated by the addition of sulfhydryl specific HPDP-biotin (0.4 mM, 50 mM 
Tris-HCl, pH 7.4) for 1 h at room temperature with end over end mixing, HAM and 
unbound biotin was removed with three sequential acetone precipitations; the 
biotinylated proteins were then affinity purified using NeutrAvidin® resin. Bound proteins 
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were eluted, subjected to SDS-PAGE, and immunoblotted with mouse anti-Flag M2 
primary antibody to detect tagged NHE1. 
Live/Dead Cell Assay 
PSN and PS120 cells were grown in media with the indicated 2BP concentrations 
and cell viability was were assessed using the viability/cytotoxicity assay from 
ThermoFisher. Live cells were counted after staining with calcein-AM while dead cells 
were determined by uptake and staining with ethidium homodimer-1. 
Cell Proliferation Assay 
Cell proliferation assay was performed by the reduction of XTT (2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxyanalide). Cells were plated at 
2,500 cells/well in a 96-well plate and incubated for 4 h to allow for attachment. Then the 
cells were incubated in DMEM media containing 0.5% FBS with the indicated agonist or 
inhibitors. After 48 h, activated XTT reagent was added to each well to attain a final 
concentration of 0.3 mg/mL and absorbance was read at 450 nm and 690 nm. 
Intracellular pH Determination 
Steady-state intracellular pH (pHi) was measured using 2ʹ,7ʹ-bis-(carboxyethyl)-5-
(and-6)-carboxyfluorescein (BCECF), a pH-sensitive fluorescent dye. Cell monolayers were 
cultured in multi-well dishes in either 20% or 0.5% serum and treated with experimental 
treatment conditions as described. Prior to pHi determination, cells were incubated with 
10 µM BCECF in PBS for 10 min at 37oC and 5% CO2. BCECF solution was replaced with 
treatment condition media to remove free dye and incubated at 37oC and 5% CO2for 10 
min at before imaging. Fluorescence was measured using a fluorescent plate reader 
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(ThermoFisher Scientific Fluoroskan Ascent Fluorescence 96/384 Well Plate Reader) at 
440:527 and 485:527 nm excitation: emission corresponding with pH independent and 
pH dependent regimes of BCECF excitation respectively. pHi was calculated by taking the 
fluorescence intensity ratio of pH independent over pH dependent fluorescence 
compared to an internal K+-Nigericin calibration curve from each well. Curves were 
generated by incubating cells in buffered 50 µM Nigericin at pH 6.5 and pH 7.5 for 5 min 
followed by the measurement of BCECF fluorescence.  
Stress Fiber Formation 
Cells were grown on quartz coverslips and following the indicated treatment were 
fixed with 3% paraformaldehyde at 4oC for 30 min and permeabilized with a 0.4% (v/v) 
solution of Triton-X100 in water for 10 min.  Actin stress fibers were stained with 0.5 
µg/mL phalloidin-Alexa Fluor 488 for 60 min in a humidified container.  Prior to mounting, 
prolong anti-fade reagent was applied.  Cells displaying significant and strong stress 
fibers98 were counted in five random fields for each slide. 
Electric Cell-substrate Impedance Sensing (ECIS) Migration Assay 
Using the ECIS Z system (ECIS® Z, Applied Biophysics Inc.), impedance was 
measured to characterize migration rates in cultured cells. Cells were seeded at 100,000 
cells/well in 8-well arrays (8W1E-PET) in DMEM medium containing 0.5% FBS and allowed 
to attach for approximately 21 h. Cells were then treated with 15 µM 2BP for 18 h after 
which a 20 sec. 16,000 Hz shock was sent to the 250 µm diameter electrode located in 
the middle of each well. Cell death occurs only to the cells attached to the electrode and 
then impedance was measured in real-time as cells migrated onto the electrode.  
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Wound Healing Assay 
Cells were seeded to each well of culture inserts (Ibidi) and incubated for 
attachment and until complete confluence at 37oC in a humidified 5% CO2 incubator. 
Twelve h prior to removal of the culture insert, cells were treated with the indicated 
concentrations of either DMSO (control) or inhibitor before removal of insert. Images of 
each wound was collected at the indicated time point and determined at four sites.  
Results are presented as an average of four trials repeated 2-3 times.  The percent wound 
remaining was calculated as compared to each initial wound. 
Results  
NHE1 is Palmitoylated in PSN Cells and Rat Tissues. 
Palmitoylation occurs on intracellular cysteine residues and regulates many functions 
including protein trafficking, membrane microdomain localization, and protein activity. 
NHE1 is a versatile protein that requires specific membrane microdomain localization and 
trafficking and is also highly modified by phosphorylation. Upon examination of the 
human NHE1 sequence we found five intracellular cysteines, with three residing on the 
highly modified C-terminal tail. Taken together, this information led us to speculate that 
NHE1 may be a palmitoylated protein. 
To test this hypothesis, we used PSN cells which stably express human NHE1 and 
various rat tissues including brain, lung, liver, and heart to explore NHE1 palmitoylation 
utilizing an acyl biotinyl exchange (ABE) method. The ABE process is an in vitro assay for 
post-hoc detection of endogenous palmitoylation. In short, the ABE is done by removing 
endogenous acyl thioesters using hydroxylamine (HAM) and replacing them with a 
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sulfhydryl-specific biotinylating reagent (HPDP biotin). Control samples treated with Tris 
in place of HAM do not incorporate the sulfhydryl reagent, demonstrating the specificity 
of labeling. Figure 4 is a representative western blot of NHE1 demonstrating the ABE 
palmitoylation assay. The presence of NHE1 in the in the HAM fraction (Palm NHE1, Fig 
4A) is representative of palmitoylated NHE1, while the absence of NHE1 in the negative 
control Tris fraction (Tris Control, Fig 4A) shows there was no non-specific incorporation 
of HPDP-biotin nor nonspecific binding to the NeutrAvidin™ resin. Additionally, 
immunoblotting samples of the HAM and Tris treated fractions for NHE1 prior to 
NeutrAvidin™ chromatography shows total NHE1 levels were not changed by the HAM 
exposure. To confirm this finding, we used metabolic labeling of PSN cells with 
radiolabeled palmitic acid132.  After labeling with 10 µM [3H]palmitic acid for 1-6 h, NHE1s 
were extracted by immunoprecipitation and subjected to SDS-PAGE followed by 
fluorography (Fig. 4B). A [3H]palmitate-labeled band appeared at a mass of ˜90kDa, the 
monomeric mass of NHE1. An additional band was present slightly below 90kDa 
representing the immature non glycosylated form of NHE1. Time course studies show 
[3H]palmitate labeling of NHE1 was scarcely detectable within 1 h and increased in 




Figure 4. S-Palmitoylation of NHE1. Determination of NHE1 palmitoylation was 
confirmed by acyl biotin exchange (ABE) in lysates from various rat tissues and PSN 
cells (A) as well as by [3H]palmitic acid labeling in PSN cells (B). A, Lysates were 
treated with Tris or hydroxylamine (HAM) and immunoblotted for NHE1.  NHE1 in 
the total portion of the immunoblot shows NHE1 present in the lysate. The presence 
of NHE1 in the HAM fraction (top panel) shows NHE1 is modified by acylation. The 
lack of NHE1 in the negative tris control fraction indicates only NHE1 modified by an 
acyl thioester was detected by the assay. (B) PSN cells were metabolically labeled 
[3H] palmitic acid for indicated times. Cells were lysed and immunoprecipitated with 
anti-NHE1 followed by SDS-PAGE/fluorography. The top panel shows [3H]palmitic 
acid incorporated into NHE1 showing NHE1 is palmitoylated consistent with the ABE. 
Results are show as representative western blots of three independent experiments.  
Figure 4 S-Palmitoylation of NHE1 
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Inhibition of NHE1 palmitoylation 
To further evaluate NHE1 palmitoylation we utilized 2-bromopalmitate (2BP), a 
well-known irreversible inhibitor of palmitoyl-acyl transferase enzymes (PATs), which 
catalyze the addition of palmitate to proteins. To begin, we assessed the potential toxicity 
of 2BP on lung fibroblast cells (PSN).  These cells, derived from NHE null PS120 fibroblasts, 
are stable expressers of epitope tagged WT human NHE1135,136. This allows us to identify 
specific NHE1 related functions as no other NHE isoforms are expressed in the parental 
cell line98.  Figure 5 shows that after treatment with either 20 µM or 50 µM 2BP, cells 
showed a minimal decrease in cell viability (5A and B) and the PSN cells began to lose 
viability only after 70 h of treatment (5A). A similar effect was observed in non NHE1 
expressing cell lines (5B). Incubation of both PSN and PS120 cells with the corresponding 
concentrations of palmitate had no effect on cell viability as expected, clearly indicating 
that potential changes in cell physiology after 2BP treatment would not be due to acute 
toxic effects. As PSN cell viability was not affected by 2BP treatment during the 18 h time 
frame, we began to assess NHE1 palmitoylation by treating PSN cells with a low 
concentration of 2BP (1 µM) for various time points. Here we saw a stepwise decrease in 
NHE1 palmitoylation from 1 h to 18 h (All p<0.05 vs. NT; 0.5 h p<0.05 vs. 9 h and 18 h) 
without the loss of total NHE1 levels (Fig. 6A). For palmitoylation analysis via ABE, control 
samples treated with Tris in place of HAM did not incorporate the sulfhydryl reagent, 
demonstrating the specificity of palmitoylation site labeling. Additionally, 
immunoblotting showed that total NHE1 levels were not changed by the 2BP incubation 
or HAM exposure (p>0.05). These results demonstrate that 2BP suppresses 
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palmitoylation of NHE1 at low concentrations, which are not toxic to the cells, and this 
suppression occurs in a time dependent manner consistent with the enzymatic nature of 
palmitoylation. To determine if increased concentrations of 2BP would further reduce 
NHE1 palmitoylation without reducing total NHE1 expression or affecting cell viability we 
treated cells with a range of 2BP concentrations for 18 h (6B). We found 2BP equally 
decreased NHE1 palmitoylation at 1 µM, 5 µM, 10 µM and 15 µM without reduction of 
total NHE1 levels (Fig. 6B). This established effective concentrations and incubation times 
in which NHE1 palmitoylation is reduced by 2BP without the reduction of total NHE1 
protein or cell toxicity, allowing us to move forward confidently using 2BP within these 
ranges and time frames to treat PSN cells and monitor the effects of 2BP on NHE1 




Figure 5. 2BP Reduces Cell Viability Only at High Concentrations for Extended 
Periods of Time. Viability of PSN and PS120 cells was assessed after incubation with 
20 µM or 50 µM 2BP. A, PSN cell viability decreased only after over 70 h of 2BP while 
incubation with palmitate had no effect on cell viability. B, 2BP treatment of PS120 
cells which do not express any isoforms of NHE only slightly decreased cell viability 
after 70 h, with palmitate having no effect.  
 




Figure 6. Inhibition of NHE1 Palmitoylation. PSN cells were treated with 1 µM 2BP for 
the indicated time (A) and indicated concentration for 18 h (B) to show inhibition of 
NHE1 palmitoylation. The western blots representative at least three independent 
experiments performed to analyze acyl thioester content. The top panel of the 
western blot represents acyl modified NHE1, measured by ABE assay. The lower panel 
of the western blots shows total NHE1 in the samples after having undergone ABE 
which is used to normalize palmitoylated NHE1. The decrease in NHE1 palmitoylation 
begins within 30 min with a 25% decrease and continues in a stepwise manner to a 
50% decrease at 18 h. When the concentration of 2BP is increased up to 15µM NHE1 
palmitoylation remains decreased by approximately 50%. Quantification of NHE1 
palmitoylation mean ± SD of at least three independent experiments performed in 
duplicate relative to control (CNT), * < p 0.05, ** < p 0.01 *** < p 0.001 versus NT (one-
way ANOVA with Tukey’s post hoc test). 
 
Figure 6 Inhibition of NHE1 Palmitoylation 
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NHE1 Transport Capacity is Decreased in Response to Palmitoylation Inhibition 
To examine the effect of 2BP on NHE1 activity, changes in intracellular pH (pHi) were 
measured using 2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) in PSN cells 
after treatment with increasing concentrations of 2BP for 18 h. pHi significantly decrease 
by 0.13 ± 0.04 and 0.25 ± 0.04 pH units in the presence of 10 µM or 15 µM 2BP, 
respectively, compared to vehicle indicating acidification of the cells and decreased 
capacity of NHE1 in maintaining cellular pH since it is the primary proton transporter in 
these cells.  
LPA is a well-known activator of NHE1 transport98, as such, we examined the impact 
of reduced NHE1 palmitoylation in the presence of 2BP on LPA-stimulated NHE1 transport 
to provide initial insight on the role of lipid modifications on NHE1 regulation and function.  
As seen in previous work under serum starved conditions (0.5% FBS)98,137, incubation with 
10 µM LPA led to a 0.18 ± 0.03 increase in pHi (Fig 7B).  Under these same serum 
conditions, pretreatment of PSN cells with 5 or 15 µM 2BP for 18 h significantly muted the 
LPA stimulated NHE1 response (Fig 7B).  While NHE1 palmitoylation is decreased with as 
low as 1 µM 2BP, change in pHi occurs only in the presence of 10 µM or higher 
concentrations of 2BP (Fig. 7A).  Taken together, Figure 7 shows 2BP treatment decreases 
pHi and suppresses the ability of LPA to increase pHi through NHE1 activity.  
Inhibiting Palmitoylation Decreases the Formation of Actin Stress Fibers 
The association of stress fibers with the plasma membrane provides critical structural 
support for this membrane and the cell as a whole138. Stress fibers are made up of actin 
filaments which bind ERM complex proteins (Ezrin, Radixin, Moesin) in order to interact 
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with the plasma membrane139,140. NHE1 directly binds Ezrin which also binds actin making 
NHE1 a critical anchoring protein for the ERM complex and creating stress fibers 
necessary for directed cell migration71. PSN cells display minimal stress fibers in a 
quiescent state which can be increased by stimulation of NHE1; specifically LPA has been 
shown to increase stress fiber formation through NHE1 activation98. To assess the effect 
of palmitoylation on stress fiber formation, cells were treated with vehicle or 15 µM 2BP 
for 18 h then stimulated with LPA after which the number of stress fibers present were 
counted. As shown in Figure 8, 2BP treatment significantly decreased stress fiber 
formation compared to LPA stimulated cells. Surprisingly, 2BP treatment alone 
significantly reduced the number of stress fibers compared to control cells. Additionally, 
when cells are treated with 2BP prior to stimulation with LPA, stress fiber formation 
remained at control levels again demonstrating the ability of 2BP to block LPA stimulation 




Figure 7. 2BP Treatment Decreases Intracellular pH. A, pHi after 2BP showing 10 
µM and 15 µM 2BP significantly decreased pHi by 0.13 ± 0.04 and 0.25 ± 0.04 pH 
units respectively compared to CNT. Quantification performed on at least three 
independent experiments performed in duplicate relative to control (CNT) * < p 
0.05, ** < p 0.01 **** < p 0.0001 versus CNT (one-way ANOVA Tukey’s post hoc 
test, mean ± SD). B, quantification of the change in pHi after LPA treatment (CNT) 
shows 2BP significantly abrogates the ability of LPA to activate NHE1. At least three 
independent experiments performed in duplicate relative to CNT ** < p 0.01 *** 
< p 0.001 versus CNT † < p 0.05 versus 5 µM (one-way ANOVA Tukey’s post hoc 
test mean ± SD).    
 
 
Figure 7 2BP Treatment Decreases Intracellular pH 
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Figure 8.  2BP Attenuates LPA Stimulated Stress Fiber Formation in PSN Cells. A, 
PSN cells with fluorescently labeled actin stress fibers showing and increase 
number of stress fiber containing cells after LPA treatment (29.7 ± 2.7%) and a 
decreased number of cells containing stress fibers after 2BP treatment (9.1 ± 2.7%). 
Cells pretreated with 2BP then stimulated with LPA had significantly less cells 
containing stress fibers compared to LPA alone (33.6 ± 2.7%). B, quantification of 
the number of cells containing stress fibers as mean ± SD of four independent 
experiments performed in duplicate relative to control (CNT), * < p 0.05, *** < p 
0.001 and ††† < p 0.001 versus LPA (one-way ANOVA with Tukey’s post hoc test, 
Mean ± SD). 
Figure 8 2BP Attenuates LPA Stimulated Stress Fiber Formation in PSN Cells 
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Inhibition of Palmitoylation Reduces Cell Migration and Proliferation  
The role of ion translocation through NHE1 in cell migration is well documented107,141–
143. NHE1 localizes to the leading edge of the cell resulting in the formation of a pH 
gradient within the cell.  The alkalization of the leading edge of the cell is important for 
the formation of stress fibers which associate directly with NHE1 through ERM binding 
and are vital for directed cell migration106,123. Thus both proton transport and stress fiber 
formation mediated through NHE1 are critical for directed cell motility in healthy cells144–
146. As such determining the effect of 2BP treatment on PSN cell migration provides 
valuable insight on potential mechanisms of NHE1 regulation by palmitoylation.   
As shown in Figure 9, PSN cells were treated with increasing concentrations of 2BP 
for 18 h then wound healing assays were performed to measure cell migration and 
calculate cell velocity. In reference to the wound healing assay, we found a dose-response 
effect to the palmitoylation inhibitor where increasing concentrations of 2BP further 
reduced the migration of cells into a vacated wound.  After 24 h, cells nearly filled the 
entirety of the wound with control cells and cells treated with lower concentrations of 
2BP (1 µM and 5 µM).  Whereas cells treated with higher concentrations of 2BP (10 µM 
and 15 µM) did not display closed wounds even after 28 h. The velocity (µm/min) of cell 
migration was examined while PSN cells were in the mid-stage of movement (between 6 
h and 12 h, see Methods for calculation). Even the lowest concentration of 2BP (1 µM) 
inhibited the cellular rate of travel from 0.64 µm/min (control) to 0.48 µm/min (2BP). We 
continued to see decreased cell motility in a concentration-dependent manner with 2BP 
treatments as high at 15 µM. Electric cell impedance system (ECIS) is a biophysical 
 49 
approach used to dynamically measure cell migration in real time. Using this method, PSN 
cells were seeded on the chamber and grown to confluence followed by treatment with 
15 µM 2BP.  After 18 h, an electric current was applied electroporating the cells resulting 
in death of cells only on the electrode thereby creating a defined wound. Cell impedance 
was then measured continuously for 7 h as cells migrated toward the electrode. Figure 
9D shows that cell impedance over time is reduced when cells are treated with 2BP 
compared to control cells. Furthermore, we found 2BP significantly reduced PSN cell 
adhesion on collagen, poly L-lysine, or Matrigel™ treated surfaces which was not 
observed with PS120 (NHE null) cells (data not shown). This indicates that global inhibition 
of palmitoylation by 2BP led to decreased cell attachment, most likely due to loss of NHE1 
palmitoylation and associated cellular functions. This could in part, explain the impact of 
2BP treatment on cell migration and velocity. Figure 9E shows treatment with 15 µM 2BP 
for 18 h significantly decreased PSN cell proliferation stimulated in the presence of 
lysophosphatidic acid (LPA).  LPA acts as a mitogen to activate NHE198 which increases cell 
proliferation, as shown in Figure 9E, while 2BP pretreatment resulted in ablation of LPA 
stimulated cell proliferation compared to no pretreatment control demonstrating 2BP 
blocks the effect of LPA on cell proliferation. Taken together, this data shows inhibiting 
palmitoylation, using 2BP, in PSN cells significantly reduces stress fiber formation leading 




Figure 9. PSN Cell Migration and Proliferation are Hindered by 2BP. Cell migration was 
evaluated by measuring ability of cells to close the wound over 28 h. A, quantification of 
wound closure after increasing concentrations of 2BP. B, representative image of the initial 
wound at 0 h with 2BP treatment resulting in reduced would closure after 24h. C, 
quantification of average cell velocity using calculated using wound healing data. D, 
representative trace of cell migration measured by electric cell impedance sensing showing 
15 µM 2BP treatment decreases the ability of cells to migrate over 7 h compared to control 
cells. E, Treatment with 15 µM 2BP for 18 hours results in significantly decreased PSN cell 
proliferation after 15 min LPA stimulation (10 µM) compared to LPA alone treated and 
control cells. Quantifications done as mean ± SD of at least three independent experiments 
relative to control (CNT), * < p 0.05, ** < p 0.01, *** < p 0.001 and ††† < p 0.001 versus LPA 
(one-way ANOVA with Tukey’s post hoc test, Mean ± S.D). 
 
Figure 9 PSN Cell Migration and Proliferation are Hindered by 2BP 
 51 
Discussion 
In this study, we show for the first time that NHE1, a SLC9 transporter, is acylated in 
both cells and rat tissues providing a novel mechanism of NHE1 regulation, which is critical 
in multiple cellular properties including cellular pH, stress fiber formation, migration, and 
proliferation. Using the PAT inhibitor, 2BP, we showed NHE1 acylation decreases in a 
time-dependent manner consistent with the irreversible nature of the inhibitor (Fig. 6A), 
and using metabolic labeling we identified the incorporation of [3H]palmitate into NHE1 
confirming palmitoylation of NHE1 also demonstrated using the ABE method (Fig. 4). 
NHE1 was fairly sensitive to 2BP treatments with decreases in NHE1 palmitoylation seen 
within 30 min of exposure to 1 µM 2BP which continued through 18 h in a stepwise 
manner (Fig. 6A). Loss of NHE1 palmitoylation plateaued after 18h of treatment with 1 
µM 2BP as increasing the concentration did not result in increased loss of NHE1 
palmitoylation Fig. 6B).  
Prior to assessing the effect of 2BP and loss of palmitoylation on NHE1 function we 
established that 2BP had no effect on the viability NHE1 expressing PSN cells or the non-
NHE1 expressing parent line (PS120) in the 18h time frame and 2BP concentrations used 
in our experiments (Fig. 5). This assured that any NHE1 functional effects seen in the 
presence of 2BP would not be attributable to cell viability but to the loss of palmitoylation. 
Since loss of palmitoylation can affect protein turnover147 we utilized 2BP concentrations 
(1-15 µM) and an 18 h incubation period where no loss of total cellular NHE1 was detected 
(see Fig. 6) assuring that changes NHE1 functional effects would not be attributable to 
loss of NHE1 itself. 
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With this in mind, we found that 2BP treatments led to decreased NHE1 
palmitoylation and altered cellular properties associated with NHE1 including cellular pH, 
stress fiber formation, migration, and proliferation.  We found a concentration dependent 
decrease in intracellular pH in response to inhibition of palmitoylation by 2BP. However, 
there was not a close correlation between loss of NHE1 palmitoylation and decreased pHi 
where 1-15 µM 2BP treatments led to equivalent loss of NHE1 palmitoylation while 1 µM 
2BP had no effect on pHi and 10-15 µM 2BP significantly decreased pHi (Fig. 7A). This 
result suggests that palmitoylation of NHE1 may not directly influence NHE1 transport 
capacity, however, this remains to be explored because NHE1 transport is dependent on 
cell surface levels of the exchanger in addition to intrinsic exchanger kinetics. The cell 
surface transport capacity of NHE1 may be sufficient to maintain cellular pH in the 
presence of lower concentrations of 2BP but not with higher concentrations suggesting 
that binding partner interactions and their palmitoylation status may be relevant in 
maintaining cellular pH via NHE1 activity. 
To begin assessing the effect of NHE1 palmitoylation on NHE1-associated cellular 
functions, we measured the effect of 2BP on pHi after stimulation with LPA. LPA is a well-
known agonist of NHE1 increasing activity and thus increasing pHi98. When cells are first 
treated with 2BP then challenged with LPA we found a reduced ability of LPA to stimulate 
NHE1 activity (Fig. 7B). This indicates LPA plays a role in regulation of NHE1 activity in a 
palmitoylation driven manner that is 2BP concentration dependent. This effect is 
consistent with the 2BP-dependent loss of LPA-stimulated cell proliferation another well-
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known NHE1-dependent function that is absent in the presence of 2BP suggesting NHE1 
palmitoylation is necessary for LPA stimulation cell proliferation and increased pHi. 
NHE1 also facilitates protein-protein interactions which regulate stress fiber 
formation through interactions with the cytoskeleton, specifically the ERM complex70,148. 
PSN cells that that express human NHE1 show reduced stress fiber formation when 
treated with 2BP (Fig. 8). In addition, LPA stimulates stress fiber formation and incubation 
of PSN cells with 2BP abolished LPA-induced stress fiber formation consistent with 2BP 
effects seen with cell proliferation and pHi. The formation of stress fibers in combination 
with increased cellular pH, regulated through NHE1 activity and localization, is critical for 
directed cell migration143,149.  We show in Figure 9 that 2BP treatment also decreases PSN 
cell migration demonstrated by reduced wound healing even at the lowest concentration 
of 2BP (1 µM) and further thwarts wound closure as 2BP concentration increases. 
Additionally, cell velocity is hindered by 2BP in a manner similar to migration with velocity 
decreasing in a stepwise manner relative to 2BP concentration. Subsequently, this 
provides preliminary evidence that palmitoylation regulates cell migration and stress fiber 
formation through a NHE1 mediated mechanism.  This suggests that palmitoylation plays 
a large role in regulation of the NHE1 and of the multiple vital cellular processes 
associated with the exchanger.   
The nature of palmitoylation is similar to that of phosphorylation as both 
modifications regulate proteins in a rapid and dynamic manner and are themselves 
regulated by enzymes which are influenced various external and internal factors. Multiple 
studies have shown palmitoylation and phosphorylation occurring on the same proteins 
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and working in a reciprocal manner to regulate various protein functions125,150. 
Phosphorylation regulates multiple NHE1 functions including activity, stress fiber 
formation, cell migration, and cell proliferation all of which are also regulated by 
palmitoylation. This suggests NHE1 regulation by palmitoylation may work in concert with 
phosphorylation to regulate these critical cellular functions. The initial characterization of 
the effects of 2BP on NHE1 mediated cellular processes provided in this study establishes 
an important role for palmitoylation in regulating NHE1 and NHE1 mediated cellular 
processes. Multiple studies including the identification of NHE1 palmitoylation sites and 
the PATs that catalyze the modification of these sites are necessary to fully understand 




PHOSPHORYLATION AND PALMITOYLATION OF THE SODIUM 
HYDROGEN EXCHANGER ISOFORM 1 (NHE1) 
Abstract 
The sodium hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed 
transmembrane protein that regulates pH and plays a vital role in multiple cellular 
processes. Additionally, NHE1 is a scaffolding protein that organizes protein complexes to 
regulate various signaling pathways within the cell. Therefore, it is important to 
understand the factors contributing to NHE1 regulation as maintenance of these critical 
cellular functions is vital to ensure a healthy cell. Phosphorylation and palmitoylation are 
both dynamic reversible posttranslational modifications (PTMs) that regulate proteins to 
influence critical cellular processes. Previous work in our lab has shown NHE1 is regulated 
by palmitoylation and that inhibition of palmitoylation in cells expressing NHE1 decreases 
NHE1 activity, as well as NHE1 associated cellular functions such as stress fiber formation 
and cell migration. NHE1 is also regulated by phosphorylation of multiple sites through 
various kinase pathways. To better understand the relationship between palmitoylation 
and phosphorylation on NHE1 we used various stimuli known to regulate multiple kinase 
pathways that control NHE1 phosphorylation and measured the impact on NHE1 
palmitoylation. Using serum, lysophosphatidic acid (LPA) and phorbol 12-myristate (PMA) 
to stimulate NHE1 phosphorylation led to increased palmitoylation of NHE1, while 
activation of the NHE1 phosphorylation with insulin led to decreased NHE1 
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palmitoylation. Additionally, we found that inhibition of PI3K, AKT, Rsk, and ROCK kinases 
all increased NHE1 palmitoylation, while inhibition of ERK1/2 decreased NHE1 
palmitoylation. Using this information, we have begun to understand how the presence 
or absence of palmitoylation and phosphorylation in a coordinated manner contributes 
to a barcode that dictates a regulatory outcome and cellular response involving the 
sodium hydrogen exchanger isoform 1 (NHE1).  
Introduction  
The sodium hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed 
transmembrane protein that regulates pH by exchanging an intracellular proton for an 
extracellular sodium ion75. NHE1 also plays a vital role in multiple cellular processes in 
addition to regulating pH such as cellular migration and proliferation, control of cell 
volume, and stress fiber formation121,122. Additionally, NHE1 is a scaffolding protein that 
organizes protein complexes to regulate various signaling pathways within the cell123,124. 
Therefore, it is important to understand the factors contributing to NHE1 regulation and 
its role in maintaining critical cellular functions vital to cell health. Regulation of NHE1 
occurs on the large intracellular C-terminus where binding partners and posttranslational 
modifications (PTMs) influence the exchanger in both short- and long-term manners. 
Major binding partners include PIP2100 and ERM71 which are important for association of 
the tail to the inner membrane leaflet and the formation of stress fibers, respectively123. 
Ca2+/calmodulin binding sites also on the C-terminal tail have been shown to play an 
important role in proton affinity and thus regulate NHE1 activity107. Additionally, multiple 
phosphorylation sites are also present on the C-terminus which have varying effects on 
 57 
NHE1 activity and the multiple cellular processes in which NHE1 plays a role. Together 
these many regulatory factors control NHE1 activity, localization, and expression, all of 
which are important for regulation of critical cellular processes.  
Phosphorylation and palmitoylation are both dynamic reversible posttranslational 
modifications (PTMs) that regulate proteins through which many critical cellular 
processes are influenced. Multiple studies have shown phosphorylation and 
palmitoylation can work together in a barcode to regulate proteins and alter cellular 
functions125,150–153. Phosphorylation is the reversible addition of a phosphoryl group from 
adenosine triphosphate (ATP) to primarily serine, threonine, or tyrosine residue and is 
broadly considered the most common posttranslational modification2,8. Phosphorylation 
introduces a charged phosphate group which induces an altered conformational change 
that can affect catalytic activity of proteins, the tendency of proteins to aggregate, and 
the ability to recruit binding partners, all of which result in altered protein function and 
cell signaling2,5. S-Palmitoylation is the addition of a 16-carbon fatty acid to a cysteine 
residue via a thioester bond. Palmitoylation is a unique lipid modification as it is 
reversible, with palmitoyl acyltransferases (PATs) catalyzing the addition of palmitate 
while acyl protein thioesterases (APTs) and palmitoyl-protein thioesterases (PPTs) 
catalyzing the removal of palmitate via a thioester bond at intracellularly available 
cysteine residues. The most well studied function of palmitoylation is trafficking of 
proteins between the organelles and increasing membrane association of cytosolic 
proteins. Recent studies have demonstrated that palmitoylation has multiple other 
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effects on proteins, particularly transmembrane proteins where effects include regulation 
of protein activity, membrane microlocalization and protein-protein interactions125,126.  
Previous work in our lab has shown NHE1 is regulated by palmitoylation and that 
inhibition of palmitoylation in cells expressing NHE1 decreases intracellular pH, which is 
associated with NHE1, as well as NHE1 associated cellular functions such as stress fiber 
formation and cell migration (Chapter II). Many binding partners and kinases interact 
directly or indirectly to regulate NHE1 activity. Identifying and understanding how these 
complex pathways are coordinated resulting in NHE1 regulation is on-going. Various 
growth factors and hormones stimulate NHE1 phosphorylation including thrombin, 
serum, epidermal growth factor, insulin, angiotensin II, phorbol esters, and 
lysophosphatidic acid (LPA). Figure 10 shows diagrams a few of the pathways that lead to 
NHE1 phosphorylation. We hypothesize these same growth factors, that stimulate NHE1 
phosphorylation, will also alter NHE1 palmitoylation. To address this hypothesis, we 
stimulated NHE1 using serum, insulin, LPA, and phorbol 12-myristate (PMA). Serum, LPA, 
and PMA all increased NHE1 phosphorylation as well as palmitoylation. Conversely, 
stimulation of NHE1 phosphorylation with insulin led to decreased NHE1 palmitoylation. 
Additionally, we inhibited several kinases that directly and indirectly lead to NHE1 
phosphorylation, to aid in understanding how different phosphorylation pathways 
participate in regulation of NHE1 by palmitoylation. This information has allowed us to 
begin understanding how the presence or absence of palmitoylation and phosphorylation 
in a coordinated manner contributes to a barcode that dictates a regulatory outcome and 




Figure 10. Pathways Involved in the Phosphorylation of NHE1. Diagram of the 
multiple pathways involved in NHE1 phosphorylation. Stimuli can activate one or more 
of these pathways initiating kinase cascades resulting in the phosphorylation of NHE1 
at various residues. 




Colorburst molecular mass standard, 2- bromopalmitate (2BP), and mouse anti-flag tag 
antibody were from Sigma Millapore and anti-NHE1(54) mouse monoclonal antibody (sc-
136239) was from Santa Cruz Biotechnology. High capacity NeutrAvidin ®-agarose resin, 
and bicinchoninic acid protein (BCA) assay reagent were from Thermo Scientific. HPDP-
biotin was from APExBio, BCECF-AM 2ʹ,7ʹ-bis-(carboxyethyl)-5-(and-6)-
carboxyfluorescein was from Molecular Probes and Nigericin was from Tocris Bioscience. 
LPA in the form of 14:0 1-myristoyl-2-hydroxy-sn-glycero-3phosphate (sodium salt) was 
from Avanti Polar Lipids. LY294002, PD98059, BID-1870, Y27632, AKT1X were from Adooq 
Biosciences. Human insulin was from Alfa Aesar and PMA was from Sigma Millapore.  
Methods 
Cell Culture 
NHE1-null cells (PS120 cells, a gift from D. Barber, University of California, San 
Francisco) derived from Chinese hamster lung fibroblasts CCL339 were used to generate 
a cell line stably expressing human NHE1 with an HA DDK epitope tag on the C terminus 
(PSN cells). These cells were maintained in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 20% fetal bovine serum, 2 mM L-glutamine, and 200 µg/ml G418 at 
37oC in a humidified 5% CO2 incubator after clonal isolation 98.   
Cell Treatments and Membrane Preparation for Palmitoylation Detection 
 
 PSN cells were subcultured, seeded on 150 mm culture dishes, and grown to 
confluency followed by treatment with experimental conditions as described. After 
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treatments, cells were washed twice with 3 mL of ice-cold buffer B (0.25 M sucrose, 10 
mM triethanolamine, 10 mM acetic acid, pH 7.8) and then scraped to one side of the plate 
using 0.5 mL of buffer B and transferred to a 2 mL microcentrifuge tube on ice.  Cells were 
then pelleted by centrifugation at 3,000 x g for 5 min at 4oC. The supernatant fraction was 
removed and 1 mL of ice-cold buffer C (0.25 M sucrose, 10 mM triethanolamine, 10 mM 
acetic acid, 1 mM EDTA, pH 7.8) containing protease inhibitors was added to break the 
pellet loose. The solution containing the loose pellet was then homogenized in a Dounce 
homogenizer with 30 up and down strokes on ice.  The resulting homogenate was 
centrifuged at 800 x g for 10 min at 4°C to pellet and remove nuclei and cell debris. The 
supernatant fraction was transferred to a new tube which was centrifuged at 16,000 x g 
for 12 min at 4°C to precipitate cell membranes. The supernatant fraction was removed 
and the pellet containing cell membranes was resuspended in 1 mL sucrose-phosphate 
(SP) buffer (10 mM sodium phosphate, 0.32M sucrose, pH 7.4) and assayed for protein 
content. 
Palmitoylation Detection using Acyl-Biotinyl Exchange (ABE) 
Adapted from Wan et al134 palmitoylated proteins are detected using three steps. 
(i) Free cysteine thiols are blocked; membranes isolated from PSN cells were solubilized 
in lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease 
inhibitors and 25 mM N-ethylmaleimide (NEM) and incubated for 20 minutes at 37oC, 
followed by acetone precipitation. Precipitated proteins were again solubilized in lysis 
buffer containing protease inhibitors and NEM and incubated at room temperature with 
end over end mixing overnight. NEM was removed by three consecutive acetone 
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precipitations in which the protein pellet was resuspended in 4SB buffer (4% SDS, 50 mM 
Tris, 5 mM EDTA, pH 7.4) followed by acetone precipitation. (ii) Thioester linked palmitoyl 
groups are specifically removed using hydroxylamine (HAM); The resuspended protein 
sample is split equally into negative control (50 mM Tris-treated) and HAM-treated (0.7 
mM) halves and incubated at room temperature for 15 min with end-over-end mixing. 
(iii) The previously palmitoylated and now free sulfhydryl groups are then biotinylated by 
the addition of sulfhydryl specific HPDP-biotin (0.4 mM, 50 mM Tris-HCl, pH 7.4) for 1 h 
at room temperature with end over end mixing, HAM and unbound biotin was removed 
with three sequential acetone precipitations; the biotinylated proteins were then affinity 
purified using NeutrAvidin® resin. Bound proteins were eluted, subjected to SDS-PAGE, 
and immunoblotted with mouse anti-Flag M2 primary antibody to detect tagged NHE1. 
Results 
Serum Stimulation Increases NHE1 Palmitoylation  
To study the influence of growth factors on NHE1 palmitoylation we began by 
looking at low serum (0.5%) and high serum (20%) conditions. Previous studies have 
shown that serum stimulates NHE1 phosphorylation through ERK signaling with Rsk 
kinase directly phosphorylating NHE1 at S703 in fibroblast cells111,154. PSN cells were 
plated, allowed to attach and after 18 h the media was replaced with media containing 
either 20% or 0.5% serum. After an additional 24 h incubation, membranes we prepared 
and NHE1 palmitoylation was analyzed using the ABE method. Figure 11 shows serum 
stimulated NHE1 is 25 ± 8.8 % more palmitoylated than when serum starved.  
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Lysophosphatidic Acid (LPA) Increases NHE1 Palmitoylation  
 
LPA, a component found in serum, acts as a mitogen signaling through G-protein 
coupled receptors activating growth factor pathways via Ras-ERK. Previous studies have 
shown LPA stimulates NHE1 phosphorylation by RhoA/ROCK and ERK/Rsk pathways98. In 
Figure 12 we show LPA stimulation increase NHE1 palmitoylation after 10 min by 79.7 ± 
16.5 % compared to no treatment. This continues in a time dependent manner with LPA 
stimulation increasing NHE1 palmitoylation 133.1 ± 18.8 % after 15 min. Moreover, when 
cells are treated with 2BP, an inhibitor of palmitoylation, for 30 min prior to LPA 
stimulation the ability of LPA to increase NHE1 palmitoylation is diminished. As both NHE1 
phosphorylation and palmitoylation are increased by LPA they may work in a cooperative 
manner to integrate the LPA stimulated pathway regulating NHE1 activity and function. 
Figure 13 shows both 5 and 15 µM 2BP plus LPA treatment decreased NHE1 
palmitoylation by 62.0 ± 9.5% and 50.6 ± 8.3 % versus LPA alone respectively. Showing 
2BP can abrogate the effect of LPA on NHE1 is consistent with previous data (Chapter II -
similar effects as those shown in Figure 8 with respect to pHi).  
Insulin Decreases NHE1 Palmitoylation  
 Insulin, another growth factor, signals through the insulin receptor to activate the 
PI3K/AKT phosphorylation pathway. Barber et al 2009 showed AKT phosphorylates NHE1 
at residue S648 to modulate stress fiber formation through NHE1 phosphorylation70. Here 
we show stimulation of cells for 10 min with 100 nM insulin decreased NHE1 
palmitoylation by 38.0 ± 5.7 % (Figure 14). Insulin treatment is known to increase NHE1 
phosphorylation and here we show the same stimulation decreases NHE1 palmitoylation. 
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This indicates that palmitoylation and phosphorylation may work in a reciprocal manner 
to regulate NHE1.  
PMA Increases NHE1 Palmitoylation 
PMA (Phorbol 12-myristate 13-acetate) is a phorbol ester (PE) that binds and activates 
PKC. Multiple studies about the effects of PEs, including PMA, have shown PEs are critical 
for regulating the lipid-interacting domain (LID) of NHE1118,155. Some studies have also 
shown treatment with PEs increases NHE1 phosphorylation however, no direct PKC 
phosphorylation site has been found on NHE169. In Figure 15 we show treatment of cells 
with 10 µM PMA increases NHE1 palmitoylation by 23.5 ± 5.0 % after 20 min of exposure. 
PMA treatment promotes the interaction of the LID region of NHE1 with the 
membrane118. Here we show PMA stimulation also increases NHE1 palmitoylation 
indicating palmitoylation could play a critical role in the association of NHE1 with the 
membrane, specifically in the LID region which contains cysteine residue 561 which could 
be a potential palmitoylation site.   
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Figure 11. NHE1 is More Palmitoylated in High Serum Conditions. 
A. Western blot representative of at least three independent 
experiments showing increased palmitoylation after 24 h serum 
stimulation as total NHE1 levels remain the same. B. 
Quantification of NHE1 palmitoylation (mean ± S.E. of at least 
three independent experiments relative to 0.5% Serum) * p < 0.05 
versus 0.5% Serum (Student’s t-test). 
Figure 11 NHE1 is More Palmitoylated in High Serum Conditions 
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Figure 12. LPA Increases NHE1 Palmitoylation A. Western blot 
representative of at least three independent experiments for each 
treatment showing palmitoylated NHE1 increasing in a time 
dependent manner following LPA treatment as total NHE1 levels 
remain the same B. Quantification of NHE1 palmitoylation 
normalized to total NHE1 present (mean ± S.E. of at least three 
independent experiments relative to control (NT) normalized to 
100%.) ** p < 0.01 and **** p < 0.0001 versus NT and † p < 0.05 
versus 10 min (one-way ANOVA with Tukey’s post hoc test). 
Figure 12 LPA Increases NHE1 Palmitoylation 
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5 µM 2BP 15 µM 2BP 
Figure 13. The Effect of LPA and 2BP Treatment on NHE1 Palmitoylation. A/C. 
Western blot representative of at least three independent experiments for each 
treatment showing 5 and 15 µM 2BP decrease NHE1 palmitoylation, LPA increase 
NHE1 palmitoylation and pretreatment with 2BP abrogates the ability of LPA to 
stimulate NHE1 palmitoylation. B/D. Quantification of NHE1 palmitoylation 
normalized to total NHE1 (mean ± S.E. of at least three independent experiments 
relative to vehicle (NT) normalized to 100%.) * p < 0.05, ** p < 0.01, *** p < 0.001 
versus NT, † p < 0.05, ††† p < 0.001 versus LPA (one-way ANOVA with Tukey’s post 
hoc test). 
 
Figure 13 The Effect of LPA and 2BP Treatment on NHE1 Palmitoylation 
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Figure 14. Insulin Decreases NHE1 Palmitoylation A. Western blot 
representative of at least three independent experiments 
showing NHE1 palmitoylation decreases after insulin treatment 
with total NHE1 levels remaining the same. B. Quantification of 
palmitoylated NHE1 normalized to total NHE1 (mean ± S.E. of at 
least three independent experiments relative to control (NT) 
normalized to 100%.) *** p < 0.001 versus NT (Student’s t-test). 
Figure 14 Insulin Decreases NHE1 Palmitoylation 
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Figure 15. PMA Increases NHE1 Palmitoylation. A. Western blot 
representative of at least three independent experiments 
showing NHE1 palmitoylation decreases after PMA treatment 
with total NHE1 levels remaining the same. B. Quantification of 
palmitoylated NHE1 normalized to total NHE1 (mean ± S.E. of at 
least three independent experiments relative to control (NT) 
normalized to 100%.) *** p < 0.001 versus NT and ††† p < 0.001 
versus 10 min (one-way ANOVA with Tukey’s post hoc test). 
 
Figure 15 PMA Increases NHE1 Palmitoylation 
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PI3K and AKT Inhibition Increases NHE1 Palmitoylation  
 Insulin signals through the PI3K/AKT pathway leading to increased NHE1 
phosphorylation at S64870. To begin assessing the involvement of kinases downstream of 
insulin binding to its receptor in regulating NHE1 palmitoylation we used LY294002 or 
AKTX1 to inhibit PI3K or AKT respectively. In Figure 16 we show NHE1 palmitoylation 
increases 37.0 ± 9.8% after treatment with 10 µM LY294002 for 20 min consistent with 
insulin pathway stimulation decreasing NHE1 palmitoylation. Additionally, treatment 
with 10 µM AKTX1 for 1 h increased NHE1 palmitoylation by 69.6 ± 5.9 % (Fig. 17). This 
aligns with the previous data showing insulin treatment decreases NHE1 palmitoylation, 
implicating the PI3K/AKT pathway as a major player linking NHE1 palmitoylation and 
phosphorylation. 
MEK Inhibition Decreases NHE1 Palmitoylation 
To further explore the role of phosphorylation on NHE1 palmitoylation we used 
PD98059 to inhibit MEK activity while cells were maintained in 20 % serum. Cells were 
treated with 10 µM PD98059 for the indicated time and NHE1 palmitoylation was 
measure using the ABE detection method. We found NHE1 palmitoylation was decreased 
by 46.6 ± 5.0 % compared to no treatment after 20 min of inhibition and was maintained 
at 30 min of treatment (Fig. 18). The MEK/ERK/Rsk kinase pathway is involved in direct 
phosphorylation of NHE1 at S770/77178. Here we show inhibition of ERK results in 
decreased palmitoylation which aligns with our earlier data showing the presence of 
serum promotes NHE1 palmitoylation. Decreased NHE1 palmitoylation after MEK 
inhibition is consistent with data in Figure 9 showing serum stimulates NHE1 
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palmitoylation linking MEK activity and NHE1 phosphorylation at S770/771 to regulation 
of NHE1 palmitoylation.  
Rsk and ROCK Inhibition Increases NHE1 Palmitoylation  
 Another kinase pathway involved in the activation of NHE1 by phosphorylation is 
the ERK/Rsk/ROCK pathway. BI-D1870 is a selective Rsk inhibitor that has been used 
extensively in previous studies to decrease NHE1 phosphorylation at S703 after serum 
stimulation156. In Figure 19 we show cells treated with 10 µM BI-D1870 for 30 min have a 
40.6 ± 6.4 % increase in NHE1 palmitoylation. Likewise, NHE1 is directly phosphorylated 
by ROCK at T65398 and when cells are treated with 10 µM of ROCK inhibitor Y-27632 for 
30 min NHE1 palmitoylation is increased by 52.3 ± 17.3 % (Fig. 20). This increase in NHE1 
palmitoylation after both ROCK and Rsk inhibition suggests stimuli increasing 
phosphorylation at S703 and T653 have an opposite effect on NHE1 palmitoylation than 





Figure 16. Inhibition of PI3K Increases NHE1 Palmitoylation. A. 
Western blot representative of at least three independent 
experiments showing NHE1 palmitoylation decreases after 
inhibition of PI3K with LY29400 treatment with total NHE1 levels 
remaining the same. B. Quantification of palmitoylated NHE1 
normalized to total NHE1 (mean ± S.E. of at least three 
independent experiments relative to vehicle (NT) normalized to 
100%.) * p < 0.05 versus NT and † p < 0.05 versus 10 min (one-way 
ANOVA with Tukey’s post hoc test). 
 
Figure 16 Inhibition of PI3K Increases NHE1 Palmitoylation 
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Figure 17. Inhibition of AKT Increases NHE1 Palmitoylation. A. 
Western blot representative of at least three independent 
experiments showing NHE1 palmitoylation decreases after 
inhibition of AKT with AKT1X treatment with total NHE1 levels 
remaining the same. B. Quantification of palmitoylated NHE1 
normalized to total NHE1 (mean ± S.E. of at least three 
independent experiments relative to vehicle (NT) normalized to 
100%.) *** p < 0.001 versus NT and ††† p < 0.001 versus 20 min 
(one-way ANOVA with Tukey’s post hoc test). 
 
Figure 17 Inhibition of AKT Increases NHE1 Palmitoylation 
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Figure 18. Inhibition of MEK Decreases NHE1 Palmitoylation. A. 
Western blot representative of at least three independent 
experiments showing NHE1 palmitoylation decreases after 
inhibition of MEK with PD98059 treatment with total NHE1 levels 
remaining the same. B. Quantification of palmitoylated NHE1 
normalized to total NHE1 (mean ± S.E. of at least three 
independent experiments relative to control (NT) normalized to 
100%.) *** p < 0.001 versus NT (one-way ANOVA with Tukey’s 
post hoc test). 
 
Figure 18 Inhibition of MEK Decreases NHE1 Palmitoylation 
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Figure 19. Inhibition of Rsk Increases NHE1 Palmitoylation. A. 
Western blot representative of at least three independent 
experiments showing NHE1 palmitoylation decreases after 
inhibition of Rsk with BI-D1870 treatment with total NHE1 levels 
remaining the same. B. Quantification of palmitoylated NHE1 
normalized to total NHE1 (mean ± S.E. of at least three 
independent experiments relative to control (NT) normalized to 
100%.) ** p < 0.01 versus NT (one-way ANOVA with Tukey’s post 
hoc test). 
 
Figure 19 Inhibition of Rsk Increases NHE1 Palmitoylation 
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Figure 20. ROCK inhibition increases NHE1 palmitoylation. A. 
Western blot representative of at least three independent 
experiments showing NHE1 palmitoylation decreases after 
inhibition of ROCK with Y-27632 treatment with total NHE1 levels 
remaining the same. B. Quantification of palmitoylated NHE1 
normalized to total NHE1 (mean ± S.E. of at least three 
independent experiments relative to control (NT) normalized to 
100%.) ** p < 0.01 versus NT (one-way ANOVA with Tukey’s post 
hoc test). 
 
Figure 20 ROCK Inhibition Increases NHE1 Palmitoylation 
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Discussion  
 NHE1 has a large number of phosphorylation sites that work together to regulate 
NHE1 activity, localization, and protein-protein interactions. All of these factors are 
important for maintaining cellular pHi as well as keeping cells in a homeostatic state. Our 
previous work has shown that in addition to phosphorylation NHE1 is also palmitoylated, 
a reversible lipid modification, that we now have linked to regulation of multiple NHE1 
associated functions (Figs. 7-9). Cell growth is regulated, in part, by pHi and stimulated by 
various growth factors and hormones. Extensive research has been done looking at the 
role of growth factors, hormones, and cell signaling molecules on NHE1 regulation with a 
focus on the specific phosphorylation pathways and kinases involved in NHE1 
phosphorylation72,77,78,98,117,120,155,157. Multiple studies have shown a link between 
phosphorylation and palmitoylation working to regulate the same protein in either a 
reciprocal or cooperative manner125,150,158–161. Here we show serum, LPA, and PMA, all 
factors that increase NHE1 phosphorylation at distinct sites, increase NHE1 palmitoylation 
and insulin, also known to specifically increase NHE1 phosphorylation, decreases NHE1 
palmitoylation. We then inhibited several kinases directly involved in NHE1 
phosphorylation and examined the effect on NHE1 palmitoylation, which is described 
below.  
 Serum contains a number of growth factor that can activate the cell and stimulate 
NHE1 activity through phosphorylation of S703 and enhance 14-3-3 binding to NHE1. 
Figure 11 shows NHE1 is more palmitoylated in the presence of high serum. Accordingly, 
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palmitoylation of NHE1 might contribute to NHE1 being in a more active state in response 
to serum.  
LPA, a component of serum, acts as a mitogen to signal through GPCRs to activate 
MAPK cascades. LPA activation of ERK results in direct phosphorylation of NHE1 at 
residues S770/771. LPA treatment increases NHE1 palmitoylation within 10 min and this 
increase continues in a time-dependent manner (Fig. 12). While LPA signals through 
multiple pathways leading to the possibility that many factors may be contributing to the 
increase in NHE1 palmitoylation here we show that LPA stimulates NHE1 palmitoylation 
and phosphorylation suggesting these modifications may work in a cooperative manner 
to regulate NHE1. Insulin signaling occurs through the PI3K/AKT phosphorylation pathway 
to phosphorylate NHE1 at S648. In Figure 14 we show cells treated with 100 nM insulin 
have decreased NHE1 palmitoylation after 10 min. This implies the AKT phosphorylation 
pathway results in a reciprocal relationship between NHE1 phosphorylation and 
palmitoylation.  
Phorbol esters such as PMA activate PKC signaling pathways. While no PKC 
phosphorylation site has been established on NHE, studies have found a defined role for 
PMA activation of NHE1. A defined binding motif for phorbol esters on NHE1 shows PMA 
acts in a PKC independent manner to activate NHE1 by increased association of the lipid 
interacting domain (LID) on NHE1 with the membrane118. In Figure 15 we show PMA 
modestly increases NHE1 palmitoylation suggesting a potential role for palmitoylation 
facilitating LID membrane interaction through a PKC mediated mechanism. A potential 
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NHE1 palmitoylation site is located within the LID area at residue C561 supporting this 
theory.  
Taken together we show various stimuli that signal through different kinase 
pathways and contribute to NHE1 palmitoylation in both cooperative and reciprocal 
manners. To continue exploring this connection between NHE1 phosphorylation and 
palmitoylation we used specific kinase inhibitors to inhibit specific signaling pathways and 
measured the effect on NHE1 palmitoylation.  
First looking at the insulin stimulated PI3K/AKT phosphorylation pathway we show 
inhibition of PI3K or AKT results in increased NHE1 palmitoylation (Figs. 16 and 17 
respectively). This is consistent with and supportive of results in Figure 14 showing insulin 
treatment decreases NHE1 palmitoylation. AKT is responsible for phosphorylation of 
NHE1 at S648 where stimulation of this pathway using insulin increases NHE1 
phosphorylation at S64870 and decreases NHE1 palmitoylation implying palmitoylation 
and phosphorylation may work to regulate NHE1 in a reciprocal manner. The ERM protein 
complex binds NHE1 between residues 550-566 which facilitates the formation of stress 
fibers. Phosphorylation of S648 on NHE1 through AKT reduces the presence of actin stress 
fibers by encouraging depolymerization. As shown previously in Figure 8, inhibition of 
palmitoylation using 2BP results in decreased formation of stress fibers and here we show 
treatment of cells with insulin which promotes S648 phosphorylation leading to 
depolymerization of stress fibers, decreases NHE1 palmitoylation (Figure 14). The ERM 
binding domain is located between residues 550-566, a potential palmitoylation site at 
residue C561 could offer an explanation for this relationship. Palmitoylation of NHE1 
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decreases stress fiber formation which could be due to the palmitate inhibiting ERM 
binding either sterically or by embedding the ERM binding motif into the membrane thus 
preventing the formation of stress fibers.  
LPA activates MEK/ERK phosphorylation pathway resulting in NHE1 
phosphorylation at S770/771. Inhibition of MEK using PD98059 decreases NHE1 
palmitoylation (Fig. 18) which aligns with LPA increasing NHE1 palmitoylation (Fig. 12). 
Phosphorylation of NHE1 S770/771 sites increases NHE1 activity in response to sustained 
acidosis. Figure 16 along with previous data showing inhibition of palmitoylation result in 
a more acidic pHi (Fig. 7) provides preliminary evidence that palmitoylation may play a 
role in cooperating with phosphorylation at these specific sites to increase NHE1 activity.  
Serum contains many growth factors and has been shown to activate the 
ERK/Rsk/ROCK pathway to phosphorylate NHE1. Rsk phosphorylates NHE1 at S703 
creating a binding pocket for 14-3-3 protein binding, which when bound decreases the 
rate of S703 dephosphorylation. Binding of 14-3-3 to NHE1 is necessary for serum 
activation of NHE1. In conjunction with serum increasing NHE1 palmitoylation (Fig. 11) 
ERK inhibition decreases NHE1 palmitoylation (Fig. 18). Interestingly when Rsk, the next 
step in the ERK pathway and kinase that directly phosphorylates S703, is inhibited NHE1 
palmitoylation increases (Fig. 19). Additionally, serum promotes phosphorylation of NHE1 
at T653 through ROCK, which when inhibited results in increased NHE1 palmitoylation 
(Fig. 20). While this seems contradictory it is likely due to the complexity of growth factor 
pathways influencing NHE1. Overall this data provides preliminary evidence that 
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palmitoylation and phosphorylation work to create specific barcoding patterns that 






 Here we show for the first time NHE1, a SLC6A transporter, is acylated in both 
cells and rat tissue providing a novel mechanism of NHE1 regulation. Using the PAT 
inhibitor, 2BP, we showed NHE1 acylation decreases in a time dependent manner. While 
2BP globally inhibits palmitoylating enzymes (PATs) we show treatment of PSN cells with 
2BP in the time and concentration range which decreases NHE1 palmitoylation also alters 
multiple cellular properties associated with NHE1 including cellular pH, stress fiber 
formation, migration, and proliferation. We determined the concentration range in which 
2BP treatment decreases NHE1 palmitoylation without causing a loss in total NHE1 
protein levels begins at a concentration of 1 µM 2BP and continues until 15 µM 2BP. 
Additionally, we begin to see decreased NHE1 palmitoylation within 30 min at even the 
lowest concentration (1 µM) of 2BP which continues through 18 h in a stepwise manner. 
This provides a range of 2BP concentration and times which are effective in reducing 
NHE1 palmitoylation without significantly effecting total NHE1 levels or cell viability which 
we subsequently used to examine the effect of decreased palmitoylation on cell 
physiology attributed to NHE1 function and can continue to be used in future 
experiments.   
We then used these concentrations and treatment times to establish 2BP 
decreases pHi which is associated with decreased NHE1 activity. To begin teasing out 
specific stimuli that have a greater effect on NHE1 palmitoylation we measured the effect 
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of 2BP on pHi after stimulation with LPA. LPA is a well-known agonist of NHE1 increasing 
activity and thus increases pHi98. When cells are first treated with 2BP and then challenged 
with LPA we found a reduced ability of LPA to stimulate NHE1 activity. This indicates LPA 
plays a greater role in regulation of NHE1 activity in a palmitoylation driven manner than 
serum.  
NHE1 also facilitates protein-protein interactions which regulates stress fiber 
formation through interactions with the cytoskeleton, specifically the ERM complex70,148. 
PSN cells treated with 2BP show reduced stress fiber formation and again when PSN cells 
were treated with 2BP, the ability of LPA to increase stress fiber formation was abolished 
as seen with pHi effects. Additionally, 2BP treatment decreases PSN cell migration shown 
by reduced wound healing, decreased cell velocity and decreased cell impendence. This 
suggests that palmitoylation plays a large role in regulation of the NHE1 and of the 
multiple vital cellular processes associated with the exchanger.  
The initial characterization of the effects of 2BP on NHE1 mediated cellular 
processes provided in this study establishes an important role for palmitoylation in 
regulating NHE1 and NHE1 mediated cellular processes. The nature of palmitoylation is 
similar to that of phosphorylation as both modifications regulate proteins in a rapid and 
dynamic manner and are themselves regulated by enzymes which are influenced various 
external and internal factors. Multiple studies have shown palmitoylation and 
phosphorylation occurring on the same proteins and working in a reciprocal manner to 
regulate various protein functions125,150. 
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NHE1 has a large number of phosphorylation sites all of which work together to 
regulate NHE1 activity, localization, and protein-protein interactions. All of these factors 
are important for maintaining cellular pHi as well as keeping cells in a homeostatic state. 
Various growth factors and hormones stimulate NHE1 phosphorylation. Here we show 
serum, LPA, and PMA, all factors that increase NHE1 phosphorylation, increase NHE1 
palmitoylation and insulin, also known to increase NHE1 phosphorylation, decreases 
NHE1 palmitoylation. We then inhibited several kinases directly involved in NHE1 
phosphorylation and examined the effect on NHE1 palmitoylation which effects cell 
physiology.  
High serum levels and the growth factors within activate the cell and stimulate 
NHE1 activity through phosphorylation of S703 and 14-3-3 binding of NHE1. Accordingly, 
palmitoylation of NHE1 might contribute to NHE1 being in a more active state in response 
to serum. LPA acts as a mitogen, signaling through GPCRs to activate MAPK cascades. 
While LPA signals through multiple pathways leading to the possibility that many factors 
may be contributing to the increase in NHE1 palmitoylation here we show that LPA 
coordinates NHE1 palmitoylation and phosphorylation to work in a cooperative manner 
on NHE1. Phorbol esters such as PMA activate PKC signaling pathways, while no PKC 
phosphorylation site has been established on NHE1, studies have found a defined role for 
PMA activation of NHE1. A defined binding motif for phorbol esters on NHE1 shows PMA 
acts in a PKC independent manner to activate NHE1 by increased association of the lipid 
interacting domain (LID) on NHE1 with the membrane118. PMA increases NHE1 
palmitoylation suggesting a potential role for palmitoylation facilitating LID membrane 
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interaction through a PMA mediated mechanism. A potential NHE1 palmitoylation site is 
located within the LID area at residue C561 supporting this theory. Insulin signaling occurs 
through the PI3K/AKT phosphorylation pathway to phosphorylate NHE1 at S648. Insulin 
decreases NHE1 palmitoylation indicating the AKT phosphorylation pathway stimulation 
results in a reciprocal relationship between NHE1 phosphorylation and palmitoylation.  
Taken together we show various stimuli that signal through different kinase 
pathways contribute to NHE1 palmitoylation in both a cooperative and reciprocal 
manner. This preliminary evidence points to palmitoylation as a possible connection point 
linking different kinase pathways that phosphorylate NHE1. To continue exploring this 
connection between NHE1 phosphorylation and palmitoylation we used specific kinase 
inhibitors and measured the effect on NHE1 palmitoylation.  
Looking at the insulin stimulated PI3K/AKT phosphorylation pathway we show 
inhibition of PI3K and AKT results in increased NHE1 palmitoylation. AKT is responsible for 
phosphorylation of NHE1 at S648, stimulation of this pathway using insulin increase NHE1 
phosphorylation at S64870 and decreases NHE1 palmitoylation implying palmitoylation 
and phosphorylation may work to regulate NHE1 in a reciprocal manner. The ERM protein 
complex binds NHE1 between residues 550-566 which facilitates the formation of stress 
fibers. Phosphorylation of S648 on NHE1 through AKT reduces actin stress fibers by 
encouraging depolymerization. Inhibition of palmitoylation using 2BP results in decreased 
formation of stress fibers and here we show treatment of cells with insulin which 
promotes S648 phosphorylation leading to depolymerization of stress fibers decreases 
NHE1 palmitoylation. The ERM binding domain is located between residues 550-566, and 
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a potential palmitoylation site at residue C561 could offer an explanation for this 
relationship. Palmitoylation of NHE1 decreases stress fiber formation which could be due 
to the palmitate inhibiting ERM biding either sterically or by embedding the ERM binding 
motif into the membrane thus preventing the formation of stress fibers.  
Inhibition of MEK using PD98059 decreases NHE1 palmitoylation which aligns with 
LPA increasing NHE1 palmitoylation. Phosphorylation of NHE1 S770/771 sites increase 
NHE1 activity in response to sustained acidosis. This along with the fact that inhibition of 
palmitoylation with 2BP results in a more acidic pHi provides preliminary evidence that 
palmitoylation may play a role in cooperating with phosphorylation at these specific sites 
to increase NHE1 activity. In conjunction with serum increasing NHE1 palmitoylation MEK 
inhibition decreases NHE1 palmitoylation. Interestingly when Rsk, a step in the MEK 
pathway and kinase that directly phosphorylates S703, is inhibited NHE1 palmitoylation 
increases. Additionally, serum promotes phosphorylation of NHE1 at T653 through ROCK, 
which when inhibited results in increased palmitoylation. While this seems contradictory, 
it is likely due to the complexity of growth factor pathways influencing NHE1. Overall this 
data provides preliminary evidence that palmitoylation and phosphorylation work to 
create specific barcoding patterns that dictate a regulatory outcome and cellular response 
involving NHE1.  
Future Directions 
Multiple studies are necessary to fully understand the effect of NHE1 
palmitoylation on cellular processes and diseases related to NHE1. A major step forward 
will be to determine the specific sites where NHE1 is palmitoylated. Once palmitoylation 
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sites are known multiple studies can be done to understand the role of NHE1 specific 
palmitoylation in NHE1 transport kinetics, localization, protein interactions, and cell 
physiology associated with NHE1. Identification of the palmitoylating and 
depalmitoylating enzymes involved in NHE1 palmitoylation would also provide targets to 
regulate and study NHE1 function in a manner similar to kinases and phosphatases.  
Additional work is necessary to understand how phosphorylation and 
palmitoylation work in a coordinated manner to regulate NHE1. These studies will focus 
on using mutations of the palmitoylation sites and phosphorylation sites to measure the 
effect on the opposite modification. However, this would be time consuming considering 
the sheer number of phosphorylation sites and potential palmitoylation sites and the 
inherent issues with mutagenesis having potential off-site effects. Mass spectrometry will 
be a useful tool to take a snapshot the effect of various stimuli on NHE1 palmitoylation 
and phosphorylation at the same time without the complications that can accompany 
mutagenesis.  
NHE1 acts as a protein scaffold by interacting with various binding partners 
including PIP2, ERM, and CHP1 and 2. NHE1 palmitoylation may alter these interactions, 
especially considering two potential palmitoylation sites are located in the PIP2 and ERM 
binding domains. Gaining a better understanding of the role palmitoylation plays in 
regulating these binding partners would provide valuable information on how 
palmitoylation is involved in protein scaffolding and on a larger scale cellular homeostasis 
and dysfunction.  
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By pursuing any one of these paths the knowledge gained will have far-reaching 
impacts on our understanding of cellular homeostasis and on the multiple diseases where 
NHE1 and palmitoylation are known to play significant roles such as cancer, Alzheimer 
disease, diabetes, epilepsy, and general neurodegeneration.  
Summary Conclusions 
Overall, we found NHE1 is palmitoylated and that palmitoylation plays a role in 
regulation of multiple vital cellular processes associated with the NHE1. Additionally, we 
gathered preliminary data showing NHE1 palmitoylation and phosphorylation 
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